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ABSTRACT 
 
Staphylococcus aureus is a Gram-positive coccus belonging to the Stapylococcaeae 
family. S. aureus causes a wide range of infections that range from skin infections to life-
threatening infections such as pneumonia and endocarditis and is the major cause of hospital 
and community-acquired infections. Despite antibiotics being available for the treatment of S. 
aureus infections, resistance to a number of antibiotics has developed over the years due to 
their improper and continuous use. S. aureus develops resistance to various drugs via 
different mechanisms, one of which is the extrusion of the antibiotics through efflux pumps 
that play a role in its acquisition of multidrug resistance. The ability of methicillin-resistant S. 
aureus to develop resistance to a variety of antibiotics is causing global concern as treatment 
options are being limited. Various antimicrobial studies carried out on purified plant-based 
flavonoids have shown that flavonoids enhance the antibacterial effect of antibiotics. 
This study analysed antibacterial effects of the antibiotics; tetracycline, ampicillin, 
methicillin and vancomycin and three flavonoids; chrysin, naringenin and 7-hydroxyflavone, 
against methicillin-sensitive ATCC 25923 (MSSA) and methicillin-resistant ATCC 33591 
(MRSA) S. aureus strains, using the Kirby-Bauer disk diffusion and microtitre microdilution 
assays. In the Kirby- Bauer assay, the antibiotics demonstrated inhibitory effects on the 
growth of MSSA ATCC 25923. However MRSA ATCC 33591 was only susceptible to 
vancomycin, with minimal inhibition zones observed with ampicillin. The flavonoids did not 
enhance or reduce the antibacterial activities of the antibiotics as the zones of inhibition sizes 
remained unchanged in the combination studies. Microtitre assay results revealed that 
naringenin enhanced the antibacterial activities of the antibiotics tetracycline and ampicillin, 
against MSSA ATCC 25923 and MRSA 33591. This was evident as calculated synergistic 
ratios by the Abbot formula showed that naringenin had an additive effect. The presence of 
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the efflux pump genes in MSSA ATCC 25923 and MRSA ATCC 33591 was compared using 
polymerase chain reaction (PCR). The mepA and gyrA genes were identified in both strains 
whereas sepA was identified in MRSA ATCC 33591. The presence of efflux pump genes in 
both MSSA ATCC 25923 and MRSA ATCC 33591 also confirmed that the presence or 
absence of the genes may contribute to antibiotic resistance. The presence of sepA in the 
MRSA and not the MSSA confirmed that this gene plays a role in conferring drug resistance. 
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1.1. INTRODUCTION 
Staphylococcus aureus (S. aureus) is a Gram-positive coccus that belongs to the 
Staphylococcaeae family. It was discovered by a surgeon, in pus from surgical abscesses in 
1880 in Aberdeen, Scotland by Alexander Ogston (Ogston 1984). It appears as “grape-like 
clusters” under the microscope and is the major cause of staphylococcal infections. S. aureus 
forms part of the normal flora found on the skin and in the nose and it has been established 
that 20% of the human population are long-term carriers (Lyon and Skurray 1987; 
Kluytmans, van Belkum et al. 1997; Tsiodras, Gold et al. 2001). When grown on solid media, 
it produces colonies with a golden-yellow appearance (Hsueh, Chen et al. 2002; Hsueh, Liu 
et al. 2002; Azeez-Akande 2010) from which its name - “aureus” meaning “golden” in Latin 
is derived. S. aureus contains a carotenoid pigment called staphyloxanthin which is 
responsible for the antioxidant properties of the bacterium. Staphyloxanthin enables it to 
escape death by reactive oxygen species and is responsible for the golden color seen in 
colonies (Clauditz, Resch et al. 2006). 
 
1.1.1. Infection 
Infection with S. aureus causes a wide variety of illnesses which include boils, 
abscesses, pimples, and impetigo scalded skin syndrome which affect the skin. It also infects 
different parts of the body and cause illnesses such as pneumonia, gastroenteritis, chest pain, 
bacteremia, endocarditis, osteomyelitis and septicemia (Bernards, Frenay et al. 1998; 
Richards, Edwards et al. 1999a; Perez-Vazquez, Vindel et al. 2009). It is clear that S. aureus 
can infect different parts of the body causing life-threatening conditions and is the leading 
cause of both hospital and community-acquired infections (Kuehnert, Hill et al. 2005; Shittu, 
Udo et al. 2009).  
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Several risk factors may predispose some people to infection with S. aureus. Those at 
risk include diabetics, young children, elderly people, people that share rooms such as those 
in boarding schools, prisons, soldiers in basic training, injection drug users, patients with skin 
infections, and patients using catheters (Becker, Friedrich et al. 2003; Kuehnert, Hill et al. 
2005; Moran and Talan 2005; Mulvey, MacDougall et al. 2005). Other risk factors include 
hospitals where people may share beds, health care personnel and patients, people with 
lowered immune systems as in the case of HIV/AIDS, cancer and transplant patients, and 
prior or unwarranted antimicrobial therapy (Fey, Said-Salim et al. 2003; Bratu, Eramo et al. 
2005; Kuehnert, Hill et al. 2005).  
 
1.1.2. Diagnosis and identification 
Guidelines have been put in place to help govern the proper and efficient 
identification and laboratory diagnosis of S. aureus. A number of tests have been set up that 
easily identify S. aureus and differentiate it from other bacteria including other 
staphylococcal species (Brown, Edwards et al. 2005). The test that can be used to 
differentiate S. aureus from other staphylococcus species is the coagulase (cell-bound and 
free coagulase) test, which is considered the standard test for routine identification of S. 
aureus (Brown, Edwards et al. 2005). S. aureus is able to produce an enzyme known as 
coagulase (clumping factor) that is able to form clots (clots plasma) (Wichelhaus, Kern et al. 
1999). This test is useful as most of the other staphylococcal species are coagulase-negative, 
and are termed coagulase-negative staphylococci (CoNS) (Brown, Edwards et al. 2005). S. 
aureus also produces the enzyme deoxyribonuclease (DNase), which is able to denature DNA 
(as seen when DNase plates are used in biochemical tests). However, confirmation tests 
should be done when positive results are obtained as CoNS are also capable of producing the 
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DNase enzyme (Barry, Lachica et al. 1973). The lipase test (with a yellow color and rancid 
odor smell) and phosphatase test (with a pink color) can also be done (Cookson 1997). Other 
tests that are used to identify S. aureus include the latex agglutination tests that detect various 
surface antigens including protein A and/or clumping factors. The only problem with these 
tests is that the specificity may be compromised due to cross-reactivity with CoNS and the 
fact that some S. aureus strains may not produce the clamping factor or protein A (Kaur, 
Talwar et al. 1988; Blake and Metcalfe 2001; van Griethuysen, Bes et al. 2001).    
Molecular-based tests have also been used to identify S. aureus and involve the use of 
Polymerase Chain Reaction (PCR). This test is specific in that it utilizes primers that have 
been designed to be species-specific and amplify specific target sites (Towner, Talbot et al. 
1998; Kearns, Seiders et al. 1999; Mason, Blevins et al. 2001; Grisold, Leitner et al. 2002). A 
real-time PCR kit, that has been commercially made, has also been employed in the 
identification of S. aureus, which detects specific sequences within the internal transcribed 
spacer (ITS) S. aureus region (Levi and Towner 2004; Harbarth, Hawkey et al. 2011).  
Blood cultures have also been used in the diagnosis of S. aureus infections, especially 
when dealing with deep-tissue infections such as endocarditis and bacteremia (Dark, Dean et 
al. 2009; Stefani 2009). However, blood culture results take time and should be coupled with 
other identification and diagnostic techniques especially when dealing with critically ill 
patients (Harbarth, Garbino et al. 2003).  Solid agar media has also been used to identify S. 
aureus due to its cluster-forming ability and its ability to ferment carbohydrates, and 
produces white-deep yellow colonies. This is as a result of indicators, inhibitory substances 
including antibiotics such as methicillin and oxacillin, that are added to the media and play a 
role in differentiating and selecting S. aureus stains including those that are methicillin-
resistant (Blanc, Wenger et al. 2003; Monsen, Olofsson et al. 2003; Safdar, Narans et al. 
2003; Perry, Davies et al. 2004). Agar media, such as mannitol salt agar (MSA), a selective 
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media containing 7- 9% NaCl, has been used. It allows the growth of S. aureus and results in 
the production of golden-yellow colonies as a result of mannitol fermentation (Safdar, Narans 
et al. 2003; Malhotra-Kumar, Abrahantes et al. 2010).  
 
1.2. VIRULENCE FACTORS 
Staphylococcus aureus has the ability to evade the immune system through the 
synthesis of various virulence factors including exotoxins (Archer 1998; Novick 2003) and 
hydrolytic enzymes (Lowy 1998; Vojtov, Ross et al. 2002), which are involved in causing 
infection (Archer 1998; Novick 2003). Some of these virulence factors include leukocidins, 
proteases, coagulase, hemolysins, enterotoxins, exfoliative toxins and immune-modulating 
factors (Tait-Kamradt, Clancy et al. 1997; Manders 1998; Rajaraman, Jack et al. 2000; 
Rooijakkers, van Kessel et al. 2005), which are produced via a number of multifarious 
regulation pathways (Bronner, Monteil et al. 2004). However, it has been shown that 
virulence factor expression patterns of S. aureus differ during host infection from when it is 
grown on media, implying that the regulation of these virulence factors is complex due to 
cellular immune factors and nutrient conditions (Oogai, Matsuo et al. 2011). 
 
1.2.1. Toxins 
S. aureus is able to secrete various exotoxins and enterotoxins, depending on the strain, and 
can be categorized into three groups, namely superantigens, exfoliative toxins, and other 
toxins. 
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1.2.1.1. Superantigens 
This group induces toxic shock syndrome (TSS) and includes the toxin TSST-1, 
which usually causes TSS linked to tampon use in women. This toxin is extremely virulent 
and causes serious S. aureus infections (Lucet, Herrmann et al. 1990; Musser, Schlievert et 
al. 1990; De Boer, Kum et al. 1999). Hypotension, shock, erythematous rash, multi-organ 
failure, fevers, and skin desquamation is characteristic of such toxins. This group also 
includes food poisoning associated with staphylococcal enterotoxins, which manifests as 
vomiting and diarrhea 1-6 hours after S. aureus ingestion (Fey, Said-Salim et al. 2003; 
Mulvey, MacDougall et al. 2005). Enterotoxins are also believed to function as T cell 
superantigens, and are frequently expressed by S. aureus clinical isolates and code for mobile 
genetic elements (Vandenesch, Naimi et al. 2003). These are responsible for binding to the 
antigen-presenting cells surfaces via the Major Histocompatibility Complex (MHC) II 
causing functional association with the T helper cells facilitated by the surface T cell 
receptors (TCR) (Llewelyn and Cohen 2002; Proft and Fraser 2003).  
 
1.2.1.2. Exfoliative toxins 
These types of toxins, which include epidermolytic toxins A and B, are associated 
with staphylococcal scaled-skin syndrome (SSSS) and are frequent in infants and young 
children and also seen  in hospital nurseries. The peeling of the skin is caused by the protease 
activity of these toxins as seen in SSSS (Lina, Gillet et al. 1997). 
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1.2.1.3. Other toxins 
Most toxins produced by staphylococci are able to form pores in the host cytoplasmic 
membrane thereby causing cellular damage (Lazarevic, Beaume et al. 2011). Examples of 
such toxins are the α (alpha), β (beta), γ (gamma) and δ (delta) hemolysins including 
bicomponent toxins, which have been shown to cause cellular damage by affecting the cell 
membrane (Jonsson, Lindberg et al. 1985; O'Callaghan, Callegan et al. 1997; Haslinger, 
Strangfeld et al. 2003). Severe necrotinizing pneumonia in children can be associated with a 
bicomponent toxin called Panton- Valentine Leukocidin (PVL) (Fey, Said-Salim et al. 2003; 
Mulvey, MacDougall et al. 2005). PVL is also responsible for lysing white blood cells and 
causes severe tissue damage that lead to chronic intermittent infections (Akpaka, Monecke et 
al. 2011) . It is commonly found in CA-MRSA isolates, and is a pore-forming toxin that 
targets neutrophils (Prevost, Cribier et al. 1995; Dufour, Gillet et al. 2002). 
 
1.2.2. Protein A 
This protein is anchored to the staphylococcal peptidoglycan pentaglycine bridges 
(chains of five glycine residues) by transpeptidaseSortase A (Schneewind, Fowler et al. 
1995). Protein A binds to the Fc region of an antibody and is an IgG-binding protein. Studies 
done on Protein A show that it contributes to the virulence of the bacteria and is considered to 
be a B cell superantigen which is also known as staphylococcal protein A (SpA) (Silverman 
and Goodyear 2006). SpA has been shown to interact with various host proteins and is a 
major anti-opsonic factor (Kim, Thammavongsa et al. 2012). Studies showed that S. aureus 
required it to bind to the Fc region of the antibody and that mutations to the genes coding for 
Protein A resulted in lowered virulence of S. aureus (Patel, Nowlan et al. 1987). Various 
recombinant forms of Protein A have been used to bind and purify a variety of antibodies by 
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immuno-affinity and chromatography. The study of transpeptidases, like sortases, is done in 
the hope of coming up with new antibiotics to target methicillin-resistant Staphylococcus 
aureus (MRSA) infections (Zhu, Lu et al. 2008). 
 
1.2.3. Role of staphyloxanthin in virulence 
Staphylococcus aureus produces staphyloxanthin, an orange-red carotenoid, which 
gives it its characteristic “golden-yellow” color and also plays a role in its virulence 
(Wieland, Feil et al. 1994; Pelz, Wieland et al. 2005). The antioxidant properties of S. aureus, 
as a result of staphyloxanthin, enable the microbe to evade death by reactive oxygen species 
(Clauditz, Resch et al. 2006; Liu, Liu et al. 2008). The effect of staphyloxanthin was assessed 
by comparing a normal strain of S. aureus to one that had been modified to lack the pigment 
(Duthie and Lorenz 1952). It was noted that the normal strain was more likely to be able to 
survive incubation with an oxidizing chemical than the mutant strain. The effect of the two 
strains was also compared by inoculating them on wounds on mice. The pigmented strains 
caused persistent abscesses while those of the unpigmented ones healed quickly (Liu, Liu et 
al. 2008). 
Evidence of the role of staphyloxanthin in enabling S. aureus to survive immune 
attacks is seen in the various tests. The susceptibility of the bacterium to antibiotics can be 
improved by designing drugs that can inhibit the production of this pigment (Liu, Essex et al. 
2005). The biosynthesis of staphyloxanthin and human cholesterol have similarities in their 
pathways and thus a drug that was developed to lower cholesterol was shown to block S. 
aureus pigmentation as well as disease progression in a mouse infection model (Liu, Liu et 
al. 2008). A study carried out on the effect of flavones on staphyloxanthin showed a 
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reduction in its production, thereby enabling the vulnerability of S. aureus to hydrogen 
peroxide (Lee, Park et al. 2012). 
 
1.3. TREATMENT 
Penicillin was usually the drug of choice in the treatment of S. aureus infection 
following its discovery, but resistance to penicillin had been reported in many countries 
following its introduction as early as 1942. In 1944, Kirby reported penicillinase-producing 
strains (Kirby 1944). Oxacillin or flucloxacillin have been used in first-line therapy and are 
penicillinase-resistant beta-lactam antibiotics. These drugs are given in combination with 
gentamicin to treat serious infections such as endocarditis (Korzeniowski and Sande 1982; 
Bayer, Bolger et al. 1998) . However, the use of gentamicin poses some controversy as its use 
can lead to kidney damage (Cosgrove, Vigliani et al. 2009). Antimicrobial susceptibility 
testing, site of infection and severity determine the duration and type of treatment given 
(Bamberger and Boyd 2005). Drugs such as intravenous nafcillin, oxacillin (Bactocill) and 
oral dicloxacillin (Dynapen) have been administered to patients not allergic to penicillin 
(Bamberger and Boyd 2005). Cephalosporins such as cephalexin (Keflex) and intravenous 
cefazolin (Ancef) have also been given as substitutes.  
Vancomycin is considered to be the best treatment option in MRSA infections. 
However, it has been shown that the use of vancomycin has a down side in that; its 
absorption in the gastrointestinal tract is rather poor, has slow bactericidal activity and also 
has numerous side effects (Levine, Fromm et al. 1991; Gould 2008; Rasmussen, Fowler et al. 
2011). Vancomycin is administered intravenously due to the low absorption experienced 
when administered orally. Nonetheless, treatment failure has been reported and some studies 
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have actually shown that treatment with β-lactams was more beneficial compared to 
treatment with vancomycin (Chang, Peacock et al. 2003; Stryjewski, Szczech et al. 2007).  
Teicoplanin, a glycopeptide, is another drug that has been used to treat S. aureus 
infections and is administered intravenously or intramuscularly. A number of studies have 
revealed that its effectiveness is similar to that of vancomycin (Rolston, Nguyen et al. 1994; 
Yalaz, Cetin et al. 2004). Other drugs such as tigecycline, Linezolid (Zyvox), daptomycin 
(Cubicin) and telavancin have also been used in treating S. aureus infections. Tigecycline is 
used in the treatment of complex skin infections and has bacteriostatic properties 
(Rasmussen, Fowler et al. 2011). Linezolid is administered orally or intravenously and has 
been used to treat pneumonia and skin and soft tissue infections as a result S. aureus infection 
(Lin, Zhang et al. 2008; Tascini, Gemignani et al. 2009) and possesses bacteriostactic 
capabilities (Bamberger and Boyd 2005). Daptomycin has shown bactericidal properties in 
“in vitro” studies and is used to treat complicated skin and soft tissue infections (Arbeit, Maki 
et al. 2004). Daptomycin is administered intravenously (Bamberger and Boyd 2005). The 
FDA approved the use of telavancin for the treatment of skin and skin-structure infections 
(Rasmussen, Fowler et al. 2011). 
 
 
 
 
 
 
 
 
 
 
                                                                                 Literature Review 
10 
 
 
 
 
Type of 
infection 
Antibiotic choice Alternate antibiotic 
choices 
Length of therapy 
Simple, uncomplicated skin infections  Five to seven days 
MSSA Cephalexin (Keflex), dicloxacillin (dynapen) Clindamycin (Cleocin)  
MRSA Clindamycin, trimethoprim/sulfamethoxazole 
(Bactrim, Septra), linezolid (Zyvox) 
–  
Complex skin and soft-tissue infections  Two to four weeks 
(varies) 
MSSA Nafcillin Cefazolin (Ancef), 
clindamycin 
 
MRSA Vancomycin (vancocin) Linezolid, daptomycin 
(Cubicin) 
 
Bacteremia  Two to four weeks 
(varies) 
MSSA Nafcillin Cetazolin, vancomycin  
MRSA Vancomycin Linezolid, daptomycin  
Catheter-related infections  Two weeks if no 
infective 
endocarditis 
MSSA Nafcillin Cefazolin, vancomycin  
MRSA Vancomycin Linezolid, daptomycin  
Osteomyelitis  Four to six weeks 
MSSA Nafcillin, cefazolin Clindamycin, quinolone 
plus rifampin (Rifadin) 
 
MRSA Vancomycin Linezolid, daptomycin  
Pneumonia  10 to 14 days 
MSSA Nafcillin Vancomycin, 
Clindamycin 
 
MRSA Vancomycin, Linezolid –  
Table 1.1. Treatment options for Staphylococcus aureus infections 
MSSA-methicillin-sensitive S. aureus, MRSA-methicillin-resistant S. aureus (Lina, Quaglia et al. 1999; Bamberger 
and Boyd 2005) 
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1.4. METHICILLIN- RESISTANT Staphylococcus aureus (MRSA) 
Methicillin-resistant Staphylococcus aureus (MRSA) was initially identified in 
hospitals. The first isolation of MRSA was done in the UK in 1961 (Jevons 1961). Since 
then, the rates of methicillin resistance have escalated causing increasing concern. Following 
the introduction methicillin in the 1960s, resistance to methicillin was detected in strains of 
Staphylococcus aureus (Grundmann, Aires-de-Sousa et al. 2006; Sakoulas and Moellering 
2008). Despite MRSA being first identified in hospitals, hospital prevention and control 
measures alone are not sufficient to fight MRSA infections and other measure have to be put 
in place.  
MRSA is considered to be the main cause of staphylococcal infections causing 
extensive deep tissue (arthritis, osteomyelitis and renal and breast abscesses) and skin and 
soft tissue (carbuncles and furuncles) infections (McCaig, McDonald et al. 2006; Daniyan, 
Galadima et al. 2011) which can be life-threatening. MRSA is responsible for causing both 
hospital-acquired/associated (HA-MRSA) and community-acquired (CA-MRSA) infections. 
Most of the CA-MRSA infections are confined to the skin and soft tissue and treatment is 
usually effective. Nonetheless, they are capable of causing illnesses much more severe than 
those caused by HA-MRSA (Deleo, Otto et al. 2010). The toxins carried by CA-MRSA, such 
as PVL and PSM, are thought to be responsible for the increased virulence and severe 
illnesses such as sepsis, toxic shock syndrome and necrotinizing pneumonia. However, it is 
unknown why the same strain of CA-MRSA can cause treatable skin infections as well as 
severe infections that can lead to death.  
 MRSA infection has shown to have spread over the last four decades with an increase 
in the global trend, causing increased and rigorous morbidity and mortality rates in the 
healthcare facilities worldwide (Kuehnert, Hill et al. 2005) A number of risk factors play a 
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role in MRSA infection and these include autoimmune diseases, immunosuppressive therapy, 
surgery, extended hospital stay, prior or undue antimicrobial therapy and being previously 
hospitalized (Kuehnert, Hill et al. 2005). MRSA-associated infections pose a challenge in the 
hospitals due to the fact this organism has become resistant to a number of antibiotics, 
thereby causing problems.  
More effective measures have to be put in place to try and prevent and control MRSA 
infections (Maranan, Moreira et al. 1997; Bratu, Eramo et al. 2005), which tend to put a toll 
on the medical and socio-economic costs. Studies carried out show that human infection is 
potentially brought about as a result of domestic animals (Weese, Caldwell et al. 2006; 
Weese, Dick et al. 2006; Weese, Rousseau et al. 2006). 
 
1.4.1. Global prevalence and incidence of MRSA  
As earlier described, MRSA strains were initially identified in the UK in 1961, shortly 
after which they developed resistance to the introduction of methicillin (Jevons, 1961). Since 
then, MRSA epidemics and endemics have been reported worldwide (Ayliffe 1997; 
Chambers 2001a; Fridkin, Hageman et al. 2003). This has led to the assumption that S. 
aureus epidemiology is changing (Boyce 1998; Herold, Immergluck et al. 1998). MRSA 
infections are causing problems for hospitals and healthcare facilities as well as numerous 
communities worldwide (Bratu, Eramo et al. 2005; Kuehnert, Hill et al. 2005; Mulvey, 
MacDougall et al. 2005). Various reports from different countries around the world indicated 
that there was an increase in the prevalence of MRSA infection and population risk. Data 
obtained from North America as well as the Centers for Disease Control and Prevention 
(CDC) in the United States of America showed that the incidence of MRSA has increased 
over the years (Hughes 1987; Garner, Jarvis et al. 1988; Horan, Culver et al. 1988; Mulvey, 
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MacDougall et al. 2005; Azeez-Akande 2010). Additional studies carried out at different 
hospitals in the US revealed that the prevalence of MRSA rose from 6% in 1998 to 50% in 
2002 (Azeez-Akande 2010). 
Published data from other countries has also shown an increase in the prevalence of 
MRSA infections. In hospital wards in France, for instance, a study carried out revealed that 
the prevalence of MRSA was 33% - 62% (in relation to S. aureus isolates) (Mangeney, 
Bakkouch et al. 1995). Studies carried out in Taiwan indicated a rise in MRSA prevalence 
from 1981-1986 (Hsueh, Chen et al. 2002; Hsueh, Liu et al. 2002). Other studies carried out 
in Japan (Lotus, Imamura et al. 1995) and the Republic of Korea (Woojoo and Seunchill 
1999) have demonstrated MRSA prevalence of 54% and 70% respectively. However, reports 
on MRSA prevalence in Africa have been very few. Moreover, in Sudan, a study conducted 
at a Khartoum hospital revealed a prevalence of 11% (Musa, Shears et al. 1999). Studies 
carried out between 1996 and 1997 in Nigeria, Cameroon, Kenya and Algeria showed MRSA 
prevalence rates of 21% – 30% (Nigerian, Cameroon and Kenya) while Algeria had a lower 
rate of less than 10% (Kesah, Ben Redjeb et al. 2003).  
Other studies have also reported MRSA incidence in Ghana (Odonkor, Newman et al. 
2012), Ethiopia (Geyid and Lemeneh 1991), Kenya (Omari, Malonza et al. 1997), Nigeria 
(Rotimi, Orebamjo et al. 1987; Okesola, Oni et al. 1999), Senegal (Sow, Wade et al. 1998), 
South Africa and Sudan (van den Ende and Rotter 1986; Peddie, Donald et al. 1988; Gardee 
and Kirby 1993; Musa, Shears et al. 1999). Additional studies need to be carried out in order 
to establish the epidemiological distribution of methicillin-resistant Staphylococcus aureus in 
other African countries. This will give a detailed outlook of MRSA infection and prevalence 
and help in its prevention and control.  
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1.4.2. Hospital-acquired MRSA (HA-MRSA) 
MRSA infections were originally detected and identified in hospitals.. Nevertheless, it 
has since been detected in the community as well as livestock with a high global prevalence 
(Stefani, Chung et al. 2012). Various epidemiological studies that show the prevalence rates 
of MRSA have been carried out. Despite these studies being different in terms of study 
design and population samples, the highest rates (>50%) have been reported in North and 
South America, Asia and Malta. Intermediate rates were reported in China, Australia, Africa 
and some European countries e.g. Portugal (49%), Greece (40%), Italy (37%) and Romania 
(34%). Low prevalence rates were reported in other European countries including The 
Netherlands and Scandinavia (Grundmann, Aanensen et al. 2010; Mejia, Zurita et al. 2010; 
Song, Hsueh et al. 2011). 
The prevalence of HA-MRSA has also been reported to have reduced in a number of 
other European countries including Austria, France, Ireland, and the UK. However, other 
European countries have had rather constant HA-MRSA prevalence rates (Grundmann, 
Aanensen et al. 2010; Mejia, Zurita et al. 2010; Song, Hsueh et al. 2011). Furthermore, when 
the percentage of MRSA in relation to HA S. aureus infections was determined, extremely 
high rates were reported in Sri Lanka (86.5%), South Korea (77.6%), Vietnam (74.1%), 
Taiwan (65.0%), Thailand (570.%) and Hong Kong (56.8%). India and The Philippines (22.6 
and 38.1% respectively) had much lower rates (Song, Hsueh et al. 2011). 
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1.4.3. Community-acquired MRSA  
Earlier studies had reported that people with known risk factors (such as contact with 
health-care facilities and having previous antimicrobial therapy) were prone to infection with 
community isolates of MRSA. However, recent studies have reported that colonization and 
transmission was seen in populations that lacked these risk factors. Another study recently 
carried out in children attending day-care centers revealed that 3% and 24% of the children in 
the respective centers were colonized with MRSA (Adcock, Pastor et al. 1998) with these 
isolates being susceptible to a number of antibiotics which were different to the multi-drug 
resistant hospital isolates. A prospective, population-based study carried out in San Francisco, 
Figure 1.1. Global prevalence of hospital-acquired methicillin-resistant Staphylococcus aureus. 
Source. (Ito, Ma et al. 2004; Grundmann, Aanensen et al. 2010; Mejia, Zurita et al. 2010; Song, Hsueh et al. 2011)  
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CA, in 2004-2005 (Liu, Liu et al. 2008) demonstrated an incidence ten-fold higher in CA-
MRSA compared to HA-MRSA (316 vs. 31 per 100 000 population) (Liu, Liu et al. 2008).  
After infection with CA-MRSA strains caused the deaths of four children from rural 
Minnesota and North Dakota in 1999, the problem was brought to national attention (CDC, 
1999). These children did not have the risk factors commonly associated with CA-MRSA 
infection, and the infections were caused by strains that were susceptible to numerous 
antibiotics, except beta-lactams. These reports provide convincing evidence that MRSA 
strains have spread to the community and are very important outpatient pathogens (Chambers 
2001b). 
Latest studies have revealed that CA-MRSA is spreading to the healthcare settings 
especially in the US, as well as other countries (Otter and French 2011). Epidemiological 
studies carried out have shown that CA-MRSA infection is high among high-risk groups such 
as poor homeless young adults, soldiers, children, prison inmates, homosexual males, 
intravenous drug users,  athletes, as well as those in day-care centers (Groom, Wolsey et al. 
2001; Weber 2005; Diep, Chambers et al. 2008; Deleo, Otto et al. 2010). Countries that have 
maintained low MRSA rates are finding the spread of CA-MRSA a challenge. This poses an 
enormous threat to public health and the community at large – especially with CA-MRSA 
infection incidence rates increasing among healthy people. 
 
1.4.4. Livestock-associated MRSA (LA-MRSA) 
In humans, LA-MRSA was initially discovered in 2003 from a reservoir belonging to 
the CC398 lineage found in pigs and cattle and has also been found in poultry (Van Cleef, 
Broens et al. 2010; van Cleef, Monnet et al. 2011). The MRSA CC398 clone was found to 
have the ability to be transmitted from animals to humans. This new clone is, however, 
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frequently asymptomatic in livestock animals. Infections associated with MRSA CC398 have 
been reported in Europe, Asia and the US (Monecke, Coombs et al. 2011). Current evidence 
has shown, however, that the spread of LA-MRSA into hospitals and/or nursing homes in 
Europe is not significant. Moreover, the spread of LA-MRSA appears to be dependent on the 
region as well as the intensity of pig farming, and studies have shown that human infections 
are likely caused by domestic animals (Weese, Dick et al. 2006). In Europe, at present, 
invasive LA-MRSA infections including nosocomial spread are unusual (Grundmann, 
Aanensen et al. 2010). Studies carried out in 51 Dutch hospitals demonstrated that 
transmission of MRSA CC398 between hospitalized patients was 72% less likely to occur 
than other MRSA strains (Wassenberg, Bootsma et al. 2011). Even though MRSA had spread 
from hospitals to nursing homes, studies carried out in 32 German nursing homes revealed 
that there was no indication of the presence of CA-MRSA or LA-MRSA strains (Pfingsten-
Wurzburg, Pieper et al. 2011).  
The carriage of LA-MRSA in Europe is believed to be common in people who 
frequently come in contact with livestock; though illnesses linked to it are quite rare (van den 
Broek, van Cleef et al. 2009). In The Netherlands, the risk factors associated with LA-MRSA 
include working in direct contact with animals on farms (Kock, Harlizius et al. 2009; van 
Cleef, Verkade et al. 2010; Graveland, Duim et al. 2011)  as well as working with live pigs in 
slaughterhouses (Van Cleef, Broens et al. 2010). Over the past few years, various cases of 
infections such as endocarditis, pneumonia, and necrotizing fasciitis have been reported 
despite the fact that MRSA CC398 is frequently associated with asymptomatic colonization 
(Ekkelenkamp, Sekkat et al. 2006; van Rijen, Van Keulen et al. 2008; Mammina, Cala et al. 
2010; Soavi, Stellini et al. 2010).  
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1.4.5. Antimicrobial resistance of MRSA 
Antimicrobial agents have been used to treat various bacterial infections since their 
discovery, and it was believed that they would contribute to the purge of these infections. 
Nevertheless, diseases considered to have been eradicated or controlled are returning as a 
result of the organisms’ ability to acquire resistance to these antibiotics (Levy and Marshall 
2004). The emergence of multi-drug resistant bacteria worldwide is preventing existing drugs 
from being effective, thus inhibiting the proper and efficient treatment of these infections and 
thereby creating both medical and socio-economic expenses (Maranan, Moreira et al. 1997; 
Carbon 1999; Bratu, Eramo et al. 2005). 
Since these bacteria developed resistance to old antibiotics rapidly, there was, and still 
is, a need for the development of new antimicrobial agents. However, resistance to these new 
antimicrobial agents is rapid and widespread; indicating that this would be the trend even 
with the new families of antimicrobial agents, thereby limiting their life expectancy (Coates, 
Hu et al. 2002) Methicillin-resistant staphylococci are among the bacteria that have 
developed resistance to a number of antimicrobial agents (Neu 1992; Norrby, Nord et al. 
2005). S. aureus is of great concern because it of its virulence, its ability to cause a wide 
range of life-threatening infections and its ability to acclimatize to various environmental 
conditions (Lowy 1998; Kennedy, Otto et al. 2008; Kim, Thammavongsa et al. 2012). 
Despite effective antimicrobials being available, S. aureus causes a mortality rate of about 
20-40% (Mylotte and McDermott 1987a; Mylotte, McDermott et al. 1987b). S. aureus is 
currently the number one cause of nosocomial and community-acquired infections 
(Grundmann, Aires-de-Sousa et al. 2006; Deurenberg, Vink et al. 2007; van Loo, Huijsdens 
et al. 2007).  
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1.4.5.1. Mechanism of antibiotic resistance 
Antimicrobial resistance results from three main strategies which include enzymatic 
inactivation of the drug (Davies 1994), target site modification (Spratt 1994), and drug 
extrusion by efflux (Lomovskaya and Bostian 2006). During target site modification, 
chemical modifications in the antibiotic target site decrease the affinity of the antibiotic to its 
binding site (Lambert 2005). In enzymatic inactivation, hydrolytic and transferase enzymes 
render the antibiotic inactive by degrading the antibiotic, as well as modifying it through 
acetylation, adenylation or phosphorylation (Over, Gur et al. 2001). Efflux pump proteins 
coded for by efflux pump genes are responsible for the extrusion of antibiotics, thus allowing 
the pathogens to avoid antimicrobial effect (Lomovskaya and Bostian 2006).  
It has been established that S. aureus developed resistance to methicillin via the mec 
operon, situated on the staphylococcal cassette chromosome mec (SCCmec). The SCC is a 
large mobile genetic element that varies in size and genetic composition among different 
strains of MRSA (Katayama, Ito et al. 2000; Hiramatsu, Cui et al. 2001). Resistance is 
facilitated by the mecA gene, which codes for an altered penicillin-binding protein (PBP2a or 
PBP2') and has a reduced affinity for binding β-lactams including penicillins, cephalosporins, 
and carbapenems (Weems 2001). These allow for resistance to all β-lactam antibiotics as well 
as other non-beta-lactam antibiotics including erythromycin, clindamycin, gentamicin and 
ciprofloxacin, due to the mecA complex that possesses insertion sites for plasmids and 
transposons which enable the development of resistance to these other classes of antibiotics. 
Thus hindering their clinical use during MRSA infections (Chambers 2001b)  
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Mutations of the mecA gene lead to modifications of the penicillin-binding protein 2a 
(PBP-2a) product, which consequently result in drug resistance. This modifications 
mechanism eventually results in the organism being resistant to β-lactams including 
additional antibiotics that pose the same target site (Stevens, Dotter et al. 2004). Antibiotic 
resistance resulting from modification of the PBP-2a protein is believed to be as a result a 
number of factors which include (i) PBP being over-produced, (ii) the bacteria possessing a 
different PBP with reduced affinity, (iii) recombination of susceptible PBPs with other 
resistant varieties or (iv) the occurrence of specific point mutations within PBPs that 
eventually lead to the decrease of their affinity for β-lactams (Hackbarth, Kocagoz et al. 
1995; Chambers 1997; Dauwalder, Lina et al. 2008). 
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Antibiotic Resistance gene(s) Gene product(s) Mechanism(s) of 
resistance 
Location(s) 
β-Lactams 1) blaz 
 
1) β-Lactamase  1) Enzymatic hydrolysis 
of β-Lactam nucleus 
1) Pl:Tn 
 2) mecA 2) PBP2a Reduced affinity for PBP 2) 
C:SCCmec 
Glycopeptides 1) Unknown 1) Altered 
petidoglycan 
1) Trapping of 
vancomycin in the cell 
wall 
1) C 
 2) 2) D-Ala-D-Lac 2) Synthesis of dipeptide 
with reduced affinity for 
vancomycin 
2) Pl:Tn 
Quinolones 1) parC 1) ParC(GrlA) 
component of 
topoisomerase IV 
1,2) Mutations in the 
QRDR region, reducing 
affinity of enzyme-DNA 
complex for quinolones 
1)C 
 2) gyrA or gyrB 2) GyrA or GyrB 
components of gyrase 
 2) C 
Aminoglycosides (e 
g gentamycin) 
Aminoglycoside-
modifying enzymes 
(e.g aac, aph) 
Acetyltransferase, 
phosphotransferase 
Acetylating and/or 
phosphorylating enzymes 
modify aminoglycosides 
Pl, Pl:Tn 
Trimethoprim-
sulfamethoxazole 
(TMP-SMZ) 
1) Sulfonamide: 
sulA 
1) Dihydropteroate 
synthase 
1) Overproduction of p-
aminobenzoic acid by 
enzyme 
1) C 
 2) TMP: dfrB 2) Dihydrofolate 
reductase (DHFR) 
2) Reduced affinity for 
DHFR 
2)C 
Oxazolidinones Rrn 23S rRNA Mutations in domain V of 
23S rRNA component of 
the 50S ribosome. 
Interferes with ribosomal 
binding 
C 
Quinupristin-
dalfopristin (Q-D) 
1) Q:ermA, ermB, 
ermC 
1) Ribosomal 
methylases 
1) Reduced binding to the 
23S ribosomal subunit 
1)Pl, C 
 2) D:vat, vatB 2) Acetyltransferases 2) Enzymatic 
modification of 
dalfopristin 
2)Pl 
Table 1.2. Mechanism of S. aureus resistance to antimicrobial agents
 
Examples of various antibiotic resistance mechanisms employed by S. aureus. (Lyon and Skurray 1987; Allignet, 
Aubert et al. 1996; Lina, Quaglia et al. 1999; Tsiodras, Gold et al. 2001). Pl, plasmid; C. chromosome; Tn, 
transposon; QRDR, quinolone resistance-determining region.  
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1.4.5.2. Methicillin resistance 
Methicillin was introduced in 1961 but methicillin-resistance by some isolates 
followed shortly after its introduction (Jevons 1961). This has resulted in the limitation of 
therapeutic agents against infections caused by methicillin-resistant isolates (Cosgrove, 
Sakoulas et al. 2003). The mecA gene is responsible for methicillin resistance (Katayama, Ito 
et al. 2000). Methicillin-sensitive Staphylococcus aureus (MSSA) can become methicillin-
resistant by acquiring the mecA gene, which is the methicillin resistance determinant 
(Hiramatsu, Cui et al. 2001). The mortality rate from severe MRSA infection has been found 
to be as high as 10% - 34% (Tumbarello, de Gaetano Donati et al. 2002). 
 
1.4.5.3. β-lactam resistance 
β-lactams include broad-spectrum penicillins, cephalosporins, monobactams and 
carbapenems. The mechanism of antimicrobial resistance by a large number of bacteria is 
through the degradation of the antibiotics by means of chromosomal-or-plasmid encoded β-
lactamases (Bush, Calmon et al. 1995). With regard to carbapenems, mutations can occur that 
result in the loss of the porin OprD, the main route of uptake (Trias and Nikaido 1990). 
SCCmec type Source Resistance Genome size (kb) Ribotype 
I Hospital Methicillin 34.3 Conserved 
II Hospital Multi-drug 53.0 Conserved 
III Hospital Multi-drug 66.9 Conserved 
IV Community Methicillin 21 – 24 Variable 
Table 1.3. MRSA classification based on type of SCCmec present 
Source: (Corkill, Anson et al. 2004; Francois, Renzi et al. 2004; Ito, Ma et al. 2004)  
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Resistance to beta- lactam antibiotics is believed to occur in two ways; (i) by the production 
of an enzyme beta- lactamase, which subsequently causes an inactivation of the beta- lactam 
antibiotics and (ii) by the expression of transpeptidases, which are resistant to antibiotic 
activity. mecA, which codes for the penicillin-binding protein PBP2a, is responsible for the 
antibiotic resistance exhibited by S. aureus (Archer and Climo 2001; Finan, Archer et al. 
2001; McKinney, Sharma et al. 2001).  
Penicillin was introduced in the early 1940s. However, penicillin-resistant 
staphylococcal strains were detected in both hospitals and the community shortly after 
(Rammelkamp and Maxon 1942). As the late 1960s approached, over 80% of both hospital-
acquired and community-acquired staphylococcal isolates were penicillin-resistant. This 
trend of resistance, initially appearing in hospitals and then extending to the community, is a 
pattern now seen even when new antimicrobial agents are introduced and resistance develops 
(Chambers 2001a). 
 
1.4.5.4. Tetracycline resistance 
Tetracycline has been widely used in the treatment of both Gram-negative and Gram-
positive bacterial infections, as well as mycolasma, rickettsiae, and protozoan parasites 
(Chopra, Lacey et al. 1974; Chopra 1975; Markham and Neyfakh 2001). Apart from its 
therapeutic use in humans and animals, tetracycline has been erratically used in animal 
husbandry for growth promotion, resulting in extensive tetracycline resistance in both Gram-
negative and Gram-positive bacteria (including S. aureus). Tetracycline resistance is achieved 
by two main mechanisms which are active efflux by tetracycline-specific pumps/transporters 
(Tet-pumps), most of which belong to the MF family (Markham and Neyfakh 2001), and 
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ribosomal protection (Schnappinger and Hillen 1996). Tet-pumps are generally spread among 
Gram-negative and Gram-positive bacteria (Roberts 1994). 
 
1.4.5.5. Aminoglycoside resistance  
The mode of action of aminoglycosides is the inhibition of protein synthesis by 
binding to the bacterial ribosomes, thereby resulting in their death. This action is mediated 
via protonated amine and/or hydroxyl interactions with the ribosomal RNA of the bacterial 
30S ribosomal subunit (Lomovskaya and Watkins 2001a). However, the need to identify 
other compounds that are capable of resisting modification by aminoglycoside modifying 
enzymes is essential in order to improve the action of these therapeutic agents (Miller, 
Sabatelli et al. 1997). 
Aminoglycoside resistance is believed to be as a result of two main mechanisms 
which are: specific enzymatic inactivation by modifying enzymes as well as resistance 
impermeability, which are considered to be the most common mechanisms (Lomovskaya and 
Watkins 2001a). Ribosomal mutations and active efflux of the drug out of the bacteria also 
contribute to aminoglycoside resistance (Macmaster, Zelinskaya et al. 2010). These enzymes 
exert their function by covalently attaching either a phosphate, nucleotide or acetyl moiety to 
either the amine and/or the alcohol key functional group of the antibiotic. This causes a 
reduction in the ribosomal binding affinity due to the change in charge. ANT (4’) IA 
aminoglycoside adenylytransferase 4’ IA is one of the aminoglycoside modifying enzymes 
found in S. aureus (Porter, Green et al. 2010; Revuelta, Corzana et al. 2010). It attaches an 
adenyl moiety to 4’hydroxyl group of a number of aminoglycosides such as kamamycin and 
gentamicin. In Staphylococcal species; it has been found that these bacteria tend to posses 
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numerous aminoglycoside modifying enzymes that lead to multiple genotypes and complex 
phenotypes (Miller, Sabatelli et al. 1997). 
Aminoglycosides were some of the very few antimicrobial agents that were not 
affected by the active extrusion brought about by multidrug resistance pumps (MDR). 
Unfortunately, however, that is not currently the case (Moore, DeShazer et al. 1999). 
 
1.4.5.6. Quinolone resistance 
When first introduced in the 1980s, the intended use of fluoroquinolones was to treat 
Gram-negative bacterial infections, but due to their ability to treat Gram-positive bacterial 
infections, they had also been used in the treatment of infections brought about by 
staphylococcal species (Gootz and Brighty 1996). However, quinolone-resistance rapidly 
emerged especially among methicillin-resistant strains, thus decreasing their use in treatment 
of staphylococcal infections (Hopper 2002).  
Fluoroquinolones exert their antimicrobial effect by inhibiting the activity of type II 
topoisomerases, DNA gyrase (encoded by the gyrA and gyrB genes) and DNA topoisomerase 
IV [encoded by the parC (grlA in S. aureus) and parE (grlB in S. aureus) genes] (Yoon, Lee 
et al. 2010). DNA gyrase is responsible for the introduction of negative superhelical twists 
into bacterial DNA, which is essential for the instigation of DNA replication, as well as aid 
the binding of initiation proteins (Hopper 2002). Topoisomerase IV is essential in ensuring 
the separation of daughter cells after DNA replication by removing the interlinking 
chromosomes (Hopper 2002). 
 Resistance to fluoroquinolones is achieved by chromosomal mutations of 
topoisomerase IV or DNA gyrase including the action of a multidrug efflux pump (Ng, 
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Trucksis et al. 1996; Hopper 2002). Alterations in amino acid sequences in vital regions of 
the enzyme-DNA complex (quinolone resistance determining region [QRDR]) consequently 
result in the reduction of quinolone affinity for both targets thus conferring resistance (Ng, 
Trucksis et al. 1996; Hopper 2002). Both single and additional mutations in amino acid 
sequence play a role fluoroquinolone resistance. Nonetheless, additional and more complex 
amino acid mutations are essential for fluoroquinolone-resistance to occur (Ng, Trucksis et al. 
1996; Hopper 2002). 
 
1.4.5.7. Vancomycin resistance 
Following the increase in methicillin resistant Staphylococcus aureus (MRSA) 
infections, the use of vancomycin to treat these infections subsequently increased, thereby 
influencing the emergence of vancomycin-resistant staphylococci (Kirst, Thompson et al. 
1998). The first report of vancomycin-resistant staphylococci was from a clinical isolate of a 
Staphylococcus hemolyticus strain (Schwalbe, Stapleton et al. 1987) and this was later 
followed by reports of vancomycin-intermediate-resistant S. aureus (VISA), in 1997 in Japan 
(Hiramatsu, Aritaka et al. 1997). More cases of VISA have further been reported in other 
countries (Hiramatsu, Hanaki et al. 1997; Smith, Pearson et al. 1999). Reports of cases of 
vancomycin-resistant S. aureus infections raise a tremendous amount of concern as this 
demonstrates complete bacterial resistance to vancomycin as well as an unusual mode of 
distribution (Hageman, Pegues et al. 2001; Ward, Johnson et al. 2001). It has been 
established that VISA result from S. aureus parent strains that are susceptible to vancomycin  
due to persistent infection (Sieradzki, Roberts et al. 1999; Smith, Pearson et al. 1999; Moore, 
Perdreau-Remington et al. 2003). Intermediate resistance to vancomycin is thought to occur 
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through sequential point mutations in major staphylococcal regulatory genes (Mwangi, Wu et 
al. 2007; Cui, Neoh et al. 2009; Cui, Li et al. 2009). 
Resistance to glycopeptides is mediated via the acquisition of the vanA gene. This 
gene codes for an enzyme that produces an alternative peptidoglycan to which vancomycin 
will not bind (Showsh, De Boever et al. 2001). It has been suggested that alterations in 
peptidoglycan biosynthesis appears to play a role in lowering vancomycin susceptibility 
(Hiramatsu, Hanaki et al. 1997). A change in peptidoglycan biosynthesis also leads to the 
reduction of cross-linkages formed between peptidoglycan strands, consequently leading to 
more D-Ala-D-Ala residues being revealed (Hanaki, Kuwahara-Arai et al. 1998a; Hanaki, 
Labischinski et al. 1998b; Hanaki, Labischinski et al. 1998c). The distorted cross-linking is as 
a result of a reduction in the levels of L-glutamine available for amidation of D-glutamate in 
the pentapeptide bridge (Walsh and Howe 2002). The increase in the amount of D-Ala-D-Ala 
residues results in the binding and trapping of vancomycin which further prevents drug 
molecules from reaching their target sites, thus rendering the bacteria vancomycin-resistant 
(Sieradzki, Roberts et al. 1999; Avison, Bennett et al. 2002). 
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1.5. PREVENTION AND CONTROL 
A wide range of MRSA infections happen in hospitals and healthcare facilities. 
Transfer of MRSA is frequent between healthcare providers and patients, mainly because 
some healthcare providers do not follow the laid-down procedures for proper hand washing 
(Tacconelli 2008). It is important for healthcare personnel to practice good hygiene in the 
healthcare facilities. Employing basic hand washing techniques is relevant in the effective 
prevention of transmission of S. aureus as it may be passed on from the healthcare provider 
to the patients and vice-versa. The spread is usually through human-to-human contact. The 
Antimicrobial agent Rate of resistance (%) 
Erythromycin 90 - 95 
Gentamycin 75 -93  
Fluoroquinolones 30 - 90 
Clindamycin 75 - 83 
Ketolides 82 - 98 
Tetracycline 18 - 82 
Trimethoprim/sulfamethoxazole 16 - 65 
Quinupristin/dalfopristin 4 - 31 
Fusidic acid 5 - 10 
Vancomycin 0 - 5 
Oxazolidinones (e.g Linezolid) 0 - 1 
Tigecycline 0 
Daptomycin 0 
Antibiotic resistance may be unpredictable in developing countries and rate may be lower in some cases. 
Source: (Hsueh, Chen et al. 2002; Hsueh, Liu et al. 2002; Rello and Diaz 2003; Azeez-Akande 2010)  
Table 1.4. Antibiotic resistance rates of MRSA 
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use of gloves and plastic aprons and the use of a private room can play a role in the 
prevention of infection as this reduces the risk of skin-on-skin contact (Boyce 2004; Boyce, 
Havill et al. 2004). Once the bacterium is introduced into the bloodstream, it can lead to a 
number of life-threatening infections (Lowy 1998). 
Ethanol has shown to be effective against MRSA and it can also be used with 
ammonium to increase the effectiveness. Nosocomial infections can be prevented by routine 
and terminal cleaning. CO2 NAV- CO2 alcohol vapor, a non-flammable that does not damage 
metals or plastics, can also be used. Antiseptic washes and shampoos can be used for  patients 
carrying the resistant strain. Antibiotic ointments can also be used in reducing MRSA 
colonization (Loeb, Main et al. 2003). 
 
1.6. EFFLUX PUMPS AND EFFLUX PUMP GENES  
Efflux pumps are transport proteins responsible for the extrusion of toxic substances, 
including nearly all classes of clinically-important antibiotics from inside the bacterial cells 
into the external environment, and are present in both antibiotic-sensitive and antibiotic-
resistant gram-negative and Gram-positive bacteria (Piddock 2006a). Efflux simply means 
the action a cell employs to pump out solutes (Van Bambeke, Balzi et al. 2000). Efflux pump 
genes and proteins can be found in both bacteria that are antibiotic-susceptible and those that 
are resistant to the antibiotic. Nevertheless, it is possible for a strain that is susceptible to an 
antibiotic to become resistant due to the overproduction and subsequent over-expression of an 
efflux pump (Levy and Marshall 2004; Stavri, Piddock et al. 2007).  
There are two mechanisms that enable an efflux mutant to become resistant to 
antibiotics and these are: (i) the efflux pump protein expression is increased or (ii) 
Substitution(s) of an amino acid in the protein may enable it to be more capable to export the 
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solute (Piddock 2006a). This enables the bacterium to become less susceptible to the 
antimicrobial agents as their intracellular concentration is reduced (Wang, Dzink-Fox et al. 
2001; Webber and Piddock 2001; Adewoye, Sutherland et al. 2002). Efflux pumps are 
capable of transporting a variety of compounds which include antibiotics of different classes, 
or can be specific to a particular compound, therefore leading to multiple drug resistance 
(MDR). This type of resistance is dependent on the species, drug and infection. The efflux 
pumps are encoded by genes. When expression of these genes is increased, it enables the 
bacterium to become even more resistant (Oethinger, Kern et al. 1998; Oethinger, Podglajen 
et al. 1998; Oethinger, Kern et al. 2000) 
 
1.6.1. Types of efflux pumps 
Efflux pumps belong to five superfamilies and are categorized into two distinct 
groups which are: primary transporters (that use the hydrolysis of ATP) and secondary 
transporters (that use protons or sodium ions for energy) (Lomovskaya and Watkins 2001b; 
Stavri, Piddock et al. 2007). The five major families include MF (major facilitator), MATE 
(multidrug and toxic efflux), RND (resistance-nodulation-cell division), SMR (small 
multidrug resistance) and ABC (ATP binding caste) (Paulsen, Brown et al. 1996; 
Lomovskaya and Watkins 2001b; Kaur 2002; Lynch 2006). 
 
1.6.1.1. Primary transporters 
Given the fact that these transporters use ATP as their energy source, they are also 
known as ATP binding cassette (ABC) transporters. These proteins can be found in both 
eukaryotes and prokaryotes and are found almost everywhere in membrane systems (Chang 
2003). An example of an ABC transporter is P-glycoprotein 1 (P-gp, MDR1) found in 
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humans, which has been frequently studied. This is responsible for the resistance exhibited to 
the cytotoxic compounds used in cancer chemotherapy (Lage 2003). Despite the lack of 
evidence linking ABC transporters to MDR in human or animal pathogens so far, it is 
believed that ABC are present in the genomes of pathogenic bacteria and probably may 
confer resistance similar to that of P-glycoprotein 1 (Piddock 2006a; Mahamoud, Chevalier et 
al. 2007). 
These transporters consist of two hydrophobic transmembrane domains and two 
cytoplasmic domains that are involved in ATP binding. The ABC transporters found in 
bacteria are highly specific for substrates such as amino acids, sugars, metallic cations, 
vitamins, organo-iron complexes including antibiotics (Higgins 2001; Chang 2003). 
 
1.6.1.2. Secondary transporters 
This group of transporters includes the major facilitator superfamily (MFS), 
resistance-nodulation-cell division (RND), small multidrug resistance (SMR) superfamily, 
drug/metabolite transporter (DMT) superfamily, multidrug and toxic compound extrusion 
(MATE) and superfamily of the multidrug/oligodaccharidyl-lipid/polysaccharide flippase 
(MOP) (Levy 2002; Piddock 2006a; Stavri, Piddock et al. 2007). The pumps belonging to the 
MFS family, to which the efflux pump NorA belongs, have been studied in detail. (Piddock 
2006a). 
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Figure 1.2. Diagrammatic representation of the five classes of bacterial efflux pumps. Diagram also showing 
the inner membrane (e.g AcrB) and outer membrane (e.g TolC , an outer membrane protein channel) accessory 
and transport proteins including a periplamic accessory protein (e.g AcrA): ABC: ATB-binding cassettes, MFS: 
major facilitator superfamily, RND: resistance-nodulation-division, SMR: small multidrug resistance, MATE: 
multidrug and toxic compound extrusion (Piddock 2006a). 
 
1.6.2. Staphylococcus aureus Efflux pumps and Efflux pump genes 
It has been established that numerous genes code for efflux pumps and a portion of 
these are believed to be MDR (Saier and Paulsen 2001). It has also been shown that genome 
size plays a role in the number of efflux pump genes. This is evident in the large genomes 
that contain large numbers of efflux pump genes (Paulsen, Chen et al. 2001). 
The NorA efflux pump is chromosomally encoded and is present in S. aureus. It 
belongs to the major facilitator superfamily (MFS) and possesses 12 transmembrane-
spanning regions (Yoshida, Bogaki et al. 1990). NorA depends on the proton motive force for 
its action and it is associated with resistance to drugs such as fluoroquinolone, ciprofloxacin 
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and ethidium (Poole 2000). Ten alleged proteins within the S. aureus genome that share the 
sequence homology with NorA have been identified (Kaatz, Seo et al. 2000). 
NorA can be found in both methicillin-sensitive S. aureus (MSSA) and methicillin- 
resistant S. aureus (MRSA). Some of the other MDR efflux pumps that have been studied are 
QacA and QacB, which are MFS pumps encoded on plasmids. Another chromosomally-
encoded MFS pump is MdeA. MepA is a multi-drug and toxin extrusion (MATE) family 
MDR pump that is also chromosomally encoded (Paulsen, Brown et al. 1996; Kaatz, 
McAleese et al. 2005). Some genes have recently been described in S. aureus and these 
include norB, norC and sdrM, which are all MFS pumps genes (Truong-Bolduc, Dunman et 
al. 2005; Yamada, Hideka et al. 2006). The sepA gene, another gene that has been described, 
codes for a transporter, which has some similarities to the SMR (staphylococcal multi-
resistance) protein family (Narui, Noguchi et al. 2002). Other S. aureus efflux pump genes 
include chromosomally encoded genes (norA, mepA, mdeA and sepA) and plasmid-encoded 
genes (qacA/B, smr, qacG, qacJ and qacH) (Kumar and Varela 2012). S aureus also 
possesses efflux pump genes grlA/grlB and gyrA/gyrB, which encode topoisomerase IV and 
DNA gyrase respectively (Ferrero, Cameron et al. 1995; Ng, Trucksis et al. 1996; Takahata, 
Yonezawa et al. 1996). 
 
1.6.3. Role of MDR pumps in antibiotic drug resistance 
The pumps are responsible for the export of substances from the bacterial cell, thereby 
allowing it to survive the hostile environment. The efflux pumps play a role in the secretion 
of intracellular metabolites and have been thought to contain components that play a role in 
pathogenicity (Lomovskaya and Watkins 2001b). It has also been shown through tissue 
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culture studies that components of RDN (resistant nodulation division) efflux pumps are 
important for invasion, adherence, and/or colonization of the host cell. 
The incidence of the over-expression of efflux pumps in clinical isolates should be 
determined so that the clinical significance of the MDR conferred by specific efflux pumps 
can be established. The measurement of over-expression can be done in two ways: (i) by 
measuring the expression of RNA (ii) by measuring protein expression using Western 
blotting. The measurement of protein expression is commonly used as it is easily available 
(Piddock 2006; Piddock 2006a). 
Despite extensive studies done on the mechanism involved in the regulation of the 
efflux pumps in laboratory-derived mutants, the actual mechanisms responsible for the 
increased efflux in clinical isolates have been shown to fall into four groups: (i) mutations on 
the local repressor gene (ii) mutations in a global regulatory gene (iii) mutations in the 
promoter region of the transporter gene and (iv) insertion elements upstream of the 
transporter gene (Piddock 2006; Piddock 2006a). 
 
1.6.4. Efflux pump inhibitors  
Efflux pump inhibitors (EPI) are used in order to counteract the resistance that is 
exhibited by the efflux pumps. These inhibitors are made in the hope that they may improve 
the efficacy of antibiotics (Lomovskaya and Watkins 2001a). The expected role for the EPI is 
to decrease the intrinsic bacterial resistance to antibiotics; reverse the acquired resistance 
associated with efflux pump overexpression; and reduce the frequency of the emergence of 
resistant mutant strains (Pages, Masi et al. 2005; Mahamoud, Chevalier et al. 2007). 
Carbonylcyanidem-chlorophenylhydrazone (CCCP), valinomycin and dinitrophenol (DNP) 
are some of the EPIs used to completely stop the efflux of different molecules. These affect 
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the bacterial membrane energy levels and are proton motive force inhibitors (Mallea, 
Chevalier et al. 1998; Thota, Reddy et al. 2010). Other inhibitors of the proton motive force 
are omeprazole, verapramil and reserpine (Neyfakh, Borsch et al. 1993). 
 
1.7. ANTIMICROBIAL ACTIVITIES OF FLAVONOIDS 
Over the years, antibiotics have been used for the treatment of various infections and 
diseases. However, due to their increased and improper use, a number of bacteria have 
developed resistance to quite a large number of them (Levy and Marshall 2004; Usha, Jose et 
al. 2010). Staphylococcus aureus, as described earlier, is one the bacteria that has developed 
resistance to numerous antibiotics. This is causing tremendous global problems in the 
healthcare sector and in the community at large (Gilbert and McBain 2003; Bratu, Eramo et 
al. 2005; Costa, Ntokou et al. 2010).It has been observed that bacteria rapidly develop 
resistance to new classes of antibiotics and the rate at which resistance develops is higher 
than the rate at which these new classes of antibiotics are manufactured., This shows that 
multi-drug resistance may develop even to new families of these antimicrobial agents. This 
situation further prevents the effectiveness of these drugs. It is for this reason that alternative 
methods that may give rise to combating these micro-organisms and managing these diseases 
should be explored (Coates, Hu et al. 2002). Natural products have been studied and used 
over the years as therapeutic agents, and have provided an important alternative route for the 
treatment of bacterial diseases (Payne, Gwynn et al. 2007). The use of plants is due to the fact 
that they can be lucidly selected for antimicrobial testing according to ethnomedicinal use 
(Cos, Vlietinck et al. 2006).  
Flavonoids are an example of plant products that have been studied and used  by 
physicians and lay healers  to treat various infections (Havsteen 1983). They are a group of 
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heterocyclic organic compounds widely distributed in plants and plant-related products and 
add colour, flavour, and processing characteristics to several foods (fruits and vegetables) and 
drinks (tea, wine) (Yang, Kotani et al. 2001; Havsteen 2002; Cushnie and Lamb 2011). 
Flavonoid compounds have a fundamental structural feature that consists of a 2-phenyl-
benzo[α]pyrane or flavane nucleus comprising two benzene rings (A and B) linked via a 
heterocyclic pyrane ring (Brown 1980). More than 400 flavonoid derivatives have been 
recognised to possess various health benefits such as anti-inflammatory (Gabor 1986; 
Middleton, Kandaswami et al. 2000) , anti-viral (Vandeputte, Kiendrebeogo et al. 2010) and 
anti-cancer (Elangovan, Sekar et al. 1994; Middleton, Kandaswami et al. 2000; Yang, Kotani 
et al. 2001); properties. Some of the other uses and applications of flavonoids include modern 
agents (Zhang, Cao et al. 2008) and adjuncts (Stapleton, Shah et al. 2007) for the treatment of 
bacterial infections; drugs for treating toxin-mediated disease (Choi, Yahiro et al. 2007); anti-
virulence therapies (Vandeputte, Kiendrebeogo et al. 2010); and capture molecules for 
removing endotoxin from pharmaceutical preparations (Delehanty, Johnson et al. 2007). 
The pharmacological activities of flavonoids are believed to be mainly due to their 
ability to inhibit certain enzymes, their ability to search for oxygen free radicals, as well as 
their ability to chelate iron (Cushnie and Lamb 2005). The number and arrangement of their 
phenolic groups is believed to be the reason for their antioxidant properties as well as their 
ability to inhibit enzymatic activities (Havsteen 1983). Fourteen classes of flavonoids have 
been identified and these are differentiated according to their chemical nature including the 
position of substituents on the A, B and C rings (Hendrich 2006) as shown in figure 1.3. 
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Over the years, the antibacterial activities of flavonoids have been studied and earlier 
research (1987-2004) has shown that they are attributed to three mechanisms (Cushnie and 
Lamb 2005) which are: damage to the cytoplasmic membrane, (caused by perforation (Ikigai, 
Nakae et al. 1993) and/or reduction in membrane fluidity (Tsuchiya and Iinuma 2000)), 
inhibition of nucleic acid synthesis (Mori, Nishino et al. 1987) caused by topoisomerase 
inhibition (Bernard, Sable et al. 1997; Plaper, Golob et al. 2003) and inhibition of energy 
metabolism caused by NADH-cytochrome c reductase inhibition (Haraguchi, Tanimoto et al. 
1998). During the period 2005-2010, supplementary confirmation has been presented that 
supports each of the outlined mechanisms. Evidence has been presented that supports two 
new mechanisms which are: inhibition of cell wall synthesis [cause by D-alanine-D-alanine 
ligase inhibition (Wu, Kong et al. 2008)] as well as inhibition of cell membrane synthesis 
[caused by inhibition of FabG (Zhang and Rock 2004; Li, Zhang et al. 2006; Zhang, Kong et 
al. 2008), FabI (Zhang, Kong et al. 2008), Rv0636 (Brown, Papaemmanouil et al. 2007) or 
KAS III (Jeong, Lee et al. 2009). 
Figure 1.3. The skeleton structure of  flavones (a class of flavonoids), including 
ring names  and position numbers (Cushnie and Lamb 2005). 
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 Since 2005, various studies that have outlined the antibacterial activities of flavonoids 
have been carried out. These have facilitated advances in their understanding and 
development, which have consequently enabled more effective and efficient ways of moving 
forward in these studies (Cushnie and Lamb 2011). Numerous structural features that 
improve the antibacterial properties of flavonoids have been identified in current medicinal 
chemistry studies (Cushnie and Lamb 2011).These studies enable the optimisation of 
flavonoid activity as well as understanding their mechanism of action (Cushnie and Lamb 
2011).  
The antibacterial activities of flavonoids have paved the way for the study of 
synergism with various antimicrobial agents. Studies have shown that flavonoids and other 
plant products play a role in enhancing the efficacy of antimicrobial drugs (some of which 
have shown to be ineffective to some bacterial agents) (Hemaiswarya, Kruthiventi et al. 
2008; Rosato, Vitali et al. 2008; Rosato, Vitali et al. 2009). Recent studies have also shown 
that some of these plant products/compounds efficiently inhibit the efflux pumps involved in 
antibiotic resistance (Schmitz, Fluit et al. 1998; Smith, Kaatz et al. 2007). Other studies have 
also shown that flavonoids have the capacity to reduce the production of virulence factors 
such as staphyloxanthin and α-hemolysin (Lee, Park et al. 2012). It is for this reason that 
more studies should be carried out in order to fully understand flavonoid activity, as well as 
increase their use as therapeutic agents to help alleviate the problems brought about as a 
result of drug resistance. 
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1.8. AIMS OF THE STUDY 
The first aim of this study was to determine the minimum inhibitory concentrations 
(MICs) of four antibiotics (tetracycline, ampicillin, methicillin and vancomycin) and three 
flavonoids (chrysin, naringenin and 7-hydroxyflavone), as well as in combination against 
methicillin-sensitive ATCC 25923 (MSSA) and methicillin-resistant ATCC 33591 (MRSA) 
S. aureus strains, using Kirby-Bauer (disk diffusion) and microtitre (microdilution) assays. 
Synergistic ratios would be calculated for the microtitre assay combination results to assess 
whether any synergistic or additive effects could be identified due to the presence of the 
flavonoids. The second aim was to compare the presence of three efflux pump genes (mepA, 
sepA and gyrA, including the house-keeping gene 16S) in the MSSA ATCC 25923 and 
MRSA ATCC 33591 strains using polymerase chain reaction (PCR).  
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CHAPTER TWO 
 
Effect of flavonoids on the in vitro antibacterial activities of 
antibiotics against methicillin-sensitive and methicillin-
resistant Staphylococcus aureus 
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2.1. ABSTRACT 
Staphylococcus aureus is the leading cause of both hospital- and community-acquired 
infections worldwide. Despite the availability of antimicrobial agents, S. aureus has managed 
to develop resistance to a substantial range of antimicrobial agents, thus limiting its 
therapeutic options; as seen in the case of methicillin-resistant S. aureus (MRSA). It is for 
this reason that alternative treatment options have been and are still being studied to alleviate 
the problems caused by the high prevalence and widespread infection rates of MRSA. Plant 
products provide a few such alternative therapies that are being studied for their distinct 
antibacterial characteristics and are generating a tremendous amount of interest. Flavonoids 
are a group of heterocyclic organic compounds present in photosynthesising cells and plant-
related products, studied for their various antibacterial properties. 
This study investigated the antibacterial effects of four antibiotics (namely 
tetracycline, ampicillin, methicillin and vancomycin) and three flavonoids (chrysin, 
naringenin and 7-hydroxyflavone) using the Kirby-Bauer disk diffusion and microtitre 
susceptibility tests. The aim was to determine the minimum inhibitory concentrations (MICs) 
of the antibiotics and flavonoids as well as to assess their effect individually and in 
combinations against a methicillin-sensitive MSSA ATCC 25923 and methicillin-resistant 
MRSA ATCC 33591 S. aureus strains. 
The disk diffusion results showed that all four antibiotics inhibited the bacterial 
growth of MSSA ATCC 25923, while only ampicillin and vancomycin had inhibitory effects 
on the MRSA ATCC 33591 strain.  None of the three flavonoids inhibited the bacterial 
growth of both MSSA ATCC 25923 and MRSA ATCC 33591. Flavonoid and antibiotic 
combinations did not enhance the inhibitory effect on the bacterial growth, as the sizes of the 
inhibition zones remained similar to those of the antibiotic controls. In the microtitre assay, 
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naringenin proved to enhance the antimicrobial activities of tetracycline and ampicillin 
against both MSSA ATCC 25923 and MRSA ATCC 33591 strains, albeit at sub-inhibitory 
concentrations that were ineffective against the two S. aureus strains. Synergystic ratio 
calculations also revealed that naringerin has additive effects when combined with the 
antibiotics in the microtitre assay. Future studies should consider the effects of naringerin on 
the multidrug resistance efflux pump genes of MSSA and MRSA. 
 
2.2. INTRODUCTION 
Staphylococcus aureus is the leading cause of serious infections in both hospitals and 
communities (Lowy 1998). It has been established that S. aureus is the most widespread 
pathogen isolated from bloodstream infections, skin and soft tissue infections, and pneumonia 
(Bernards, Frenay et al. 1998; Pfaller, Jones et al. 1999; Deresinski 2005). Pneumonia has 
proven to be the most common disease associated with S. aureus infection, causing the 
highest mortality and morbidity rates in hospitals despite appropriate antimicrobial therapy 
being administered early (Rubinstein, Kollef et al. 2008). Not only is S. aureus responsible 
for causing pneumonia in hospitals, it is also responsible for causing community-acquired 
fatal necrotising pneumonia, despite community-acquired infections being mainly associated 
with the skin (Kollef 2005). S. aureus has been shown to be an important causative agent of 
community-acquired pneumonia in healthy children and adults (Kollef, Shorr et al. 2005) 
 Despite efforts to combat S. aureus infection, it has been able to develop resistance to 
a variety of antimicrobial agents, leading to complications brought about by the limitation in 
therapeutic options and in so doing creating a health-care burden (Chuang, Hsiao et al. 2012). 
This is evident particularly when dealing with methicillin-resistant strains, which count 
among the most important nosocomial and community-associated pathogens worldwide 
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(Frazee, Lynn et al. 2005; Kuehnert, Hill et al. 2005; van Loo, Huijsdens et al. 2007; Shittu, 
Nubel et al. 2009). 
Methicillin-resistant S. aureus (MRSA) was first isolated in the United Kingdom in 
1961 (Jevons 1961) and, since then, methicillin-resistance rates among S. aureus strains have 
increased and account for approximately 50% of all S. aureus isolates (Adcock 2002). In 
1980, as a result of the increased resistance exhibited by MRSA to a wide range of 
antimicrobial agents, with the exception of glycopeptides antibiotics, vancomycin usage 
increased over the years, thereby increasing the chances that S. aureus would develop 
vancomycin-resistance (Kirst, Thompson et al. 1998). Tetracycline has been used on a large 
scale in the treatment of Gram-positive and Gram-negative infections and animal husbandry 
for promoting growth. It is for this reason that resistance to tetracycline has developed 
(Lomovskaya and Watkins 2001a). S. aureus has shown resistance to β-lactams, with the 
resistance mechanism being mainly due to chromosomal or pasmid encoded β-lactamases 
(Bush, Calmon et al. 1995). Other drugs to which S. aureus has shown resistance include 
erythromycin, clindamycin, gentamicin, ciprofloxacin, trimethoprim/sulphamexaxole and 
linezolid (Styers, Sheehan et al. 2006). Resistance of S. aureus to various agents is the result 
of a variety of factors, including cellular changes (which prevent the accumulation of 
antimicrobial agents), changes in the cell envelope (which decrease the uptake of these 
agents) or the expression of efflux mechanisms (Poole 2002; Gilbert and McBain 2003; 
Russell 2003; Piddock 2006a).  
The increased ability of S. aureus to develop multidrug resistance has limited the 
options for therapeutic treatment, and that resistance is believed to have been caused by the 
unsystematic and inappropriate use of the current antimicrobial drugs available (Usha, Jose et 
al. 2010) which create challenges for overall global health  (Stuart and Bonnie 2004; 
Olayinka, Anthony et al. 2009). However, the rate at which new antibiotics are being 
 
 
 
 
                                                                                                                                                                                       Chapter 2 
75 
 
developed is much lower than the rate at which antibiotic resistance is being developed, 
making it difficult to combat staphylococcal infections (Hancock 2005). It is for this reason 
that new drugs that exhibit reduced resistance to these pathogens have to be investigated 
(Sarkar, Kumar et al. 2003; Fischbach and Walsh 2009). However, some diseases that were 
believed to have been eradicated and controlled re-emerge even after the introduction of new 
antimicrobial agents, suggesting that even the new antimicrobial agents may not be effective 
for long because of the high bacterial capacity to develop resistance (Coates, Hu et al. 2002; 
Levy and Marshall 2004; Gould 2007). As a result of the increased emergence of multidrug 
resistant microorganisms and the need to combat them, alternative methods have to be 
explored.  
Natural products have shown to be effective against many bacterial diseases (Payne, 
Gwynn et al. 2007) and increasingly interest is being shown in plant-derived compounds 
(Rukayadi, Lee et al. 2009; Guzman, Gupta et al. 2010). This is because plants can be 
selected and used for antibacterial testing (Cos, Vlietinck et al. 2006). Plants contain 
compounds such as alkaloids, tannis, terpenoids and flavonoids, which have been shown to 
possess antimicrobial characteristics, thus allowing them to be used as antimicrobial agents 
(Cowan 1999; Lewis and Ausubel 2006). Flavonoids are a group of heterocyclic organic 
compounds present in photosynthesising cells and plant-related products such as honey and 
propolis (Havsteen 1983; Havsteen 2002). They have been identified in vegetables, nuts, 
fruits, seeds, stems, flowers, wine and tea (Middleton, Kandaswami et al. 2000). Flavonoid 
compounds have a fundamental structural feature that consists of a 2-phenyl-benzo[α]pyrane 
or flavane nucleus comprising two benzene rings (A and B) linked via a heterocyclic pyrane 
ring (Brown 1980). Flavonoids reportedly contain numerous beneficial medicinal properties 
that include antimicrobial activity, anti-inflammatory activity, enzyme inhibition, oestrogenic 
activity (Havsteen 1983), anti-allergic activity, antioxidant activity (Middleton, Kandaswami 
 
 
 
 
                                                                                                                                                                                       Chapter 2 
76 
 
et al. 2000), vascular and cytotoxic antitumor activities (Harborne and Williams 2000), 
antivirulence (Vandeputte, Kiendrebeogo et al. 2010). Flavonoids have been used to treat 
toxin-mediated disease and bacterial infections and it has been shown that when different 
flavonoids are combined, their bacterial and bacteriostatic actions are enhanced (Fukai, 
Marumo et al. 2002; Choi, Yahiro et al. 2007) A number of studies carried out have reported 
interactions between flavonoids and mammalian cells (Harborne and Williams 2000; 
Middleton, Kandaswami et al. 2000). 
The aim of this study was to examine the antimicrobial activities of antibiotics 
(methicillin, vancomycin, tetracycline and ampicillin) and flavonoids (naringenin, chrysin 
and 7-hyroxyflavone) on their own, and in combination against methicillin-sensitive (MSSA) 
ATCC 25923 and methicillin-resistant (MRSA) ATCC 33591 S. aureus strains.  
 
2.3. MATERIALS AND METHODS 
2.3.1. Bacterial strains and growth conditions 
The bacterial isolates used for the study were S. aureus strains ATCC 25923 and 
ATCC 33591, representing methicillin-sensitive and -resistant strains respectively, obtained 
from the American Type Culture Collection (ATCC). The bacterial strains were cultured on 
tryptone soy agar (TSA) (Oxoid Ltd, UK) plates and incubated at 37ºC, overnight. A single 
colony forming unit (CFU) was inoculated into tryptone soy broth (TSB) (Oxoid Ltd, UK) 
and incubated at 37°C, with shaking for 16-18 hours. 100 µl of the overnight culture was later 
inoculated into 5ml TSB for 5-8 hours until a turbidity equivalent to 0.5 McFarland standard 
was reached, (~ 1 × 10
8 
to 2 × 10
8 
CFU/ml). 
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2.3.2. Antibiotics and flavonoids 
The antibiotics and flavonoids used were purchased in powder form from Sigma-
Aldrich, USA. The antibiotics included methicillin, vancomycin, tetracycline and ampicillin. 
The flavonoids used were chrysin, naringenin and 7-hydroxyflavone. All the antibiotics and 
flavonoids were used in the Kirby-Bauer disk diffusion assay for both the combination 
studies but only tetracycline and ampicillin were used for the combination studies in the 
microtitre assay. Naringenin was the only flavonoid that was used in the microtitre assay as 
chrysin and 7-hydroxyflavone formed suspensions when dissolved in the solvent. 
 
2.3.3. Antimicrobial susceptibility testing 
The minimum inhibitory concentrations (MICs) of the antibiotics and flavonoids were 
determined as outlined by the Clinical and Laboratory Standards Institute (CLSI 2007) for 
both the Kirby-Bauer and microtitre assays. 
 
2.3.3.1. Disk diffusion susceptibility test (Kirby-Bauer assay) 
The antibiotics and flavonoids were made up and serially diluted in 100% dimethyl 
sulfoxide (DMSO) to yield concentrations ranging from 1.25 to 50 µg/ml and 0.002 mg/ml to 
2 mg/ml for antibiotics and flavonoids, respectively. 40 µl of each antibiotic and flavonoid 
concentration was then loaded onto Munktell filter disks previously sterilised through 
autoclaving, in triplicate and placed in the incubator overnight to dry. 40 µl of the solvent 
(DMSO) was also loaded onto a control disk to assess and confirm that it would not have an 
effect on the bacterial growth at the maximum concentration used (100%). 100 µl of the 
MSSA ATCC 25923 and MRSA ATCC 33591 overnight culture, was inoculated in 5ml TSB 
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and incubated for 5-8 hours at 37ºC with shaking until an optical density at 600 nm (OD600 
nm) of 0.6 was reached, exhibiting turbidity equivalent to that of 0.5 McFarland standard. 100 
µl of the bacterial culture was then spread onto TSA plates and allowed to dry for between 
10-15 minutes to allow any excess moisture to be absorbed before the disks were applied. 
The disks were then placed onto the agar plates and incubated at 37ºC for 18 hours. Inhibition 
zones were then measured and recorded. 
For the combination studies, concentrations of antibiotics that had zone sizes big 
enough to show antagonism but small enough to show synergy were used. The antibiotic 
concentrations chosen for the combination studies were 1.25, 2.5, 5, and 12 µg/ml, for 
tetracycline, ampicillin, methicillin and vancomycin respectively. These antibiotic 
concentrations were combined with flavonoid concentrations ranging from 0.002 mg/ml to 2 
mg/ml for all three flavonoids used. The antibiotic and flavonoid combination mixtures were 
then serially diluted and 40 µl loaded onto disks, in triplicate, and allowed to dry by 
incubating them at 37ºC overnight. Control disks were also included that contained 40 µl of 
each antibiotic at the chosen concentration as well as a DMSO control disk. 100 µl of MSSA 
ATCC 25923 and MRSA ATCC 33591 overnight culture was inoculated in 5 ml TSB and 
incubated for 5-8 hours at 37ºC with shaking until an optical density at 600 nm (OD600 nm) of 
0.6 was reached and then spread onto TSA plates. The disks were then placed onto the agar 
plates and incubated at 37ºC for 18 hours. Inhibition zones were then measured and recorded. 
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2.3.3.2. Microdilution susceptibility test (Microtitre assay) 
Two antibiotics – tetracycline and ampicillin – and the flavonoid naringenin were 
chosen for the microtitre assay. The bacterial strains were first grown on TSA plates 
overnight at 37ºC and then inoculated into 5 ml TSB broth and incubated at 37ºC with 
shaking for 4-6 hours until an optical density at 600 nm (OD600 nm) of 0.6 was reached 
exhibiting turbidity equivalent to that of 0.5 McFarland standard. This was then added to 15 
ml of warm fresh broth to further dilute the bacterial culture. The experiments were carried 
out in 96 well microtitre plates and the MICs of the antibiotics for this microtitre 
microdilution method were determined as given by the Clinical and Laboratory Standards 
Institute (CLSI 2007). The concentrations used ranged from 0.05165 µg/ml to 1 µg/ml for 
ampicillin and 0.0625 µg/ml - 32 µg/ml for tetracycline and these were made up in two-fold 
serial dilutions. The concentrations used for naringenin remained the same ranging from 2 
mg/ml to 0.002 mg/ml.  
The antibiotics were dissolved in 1ml distilled water and naringenin was dissolved in 
1 ml of 99 % methanol. It was established that at 5%, methanol did not have an effect on 
bacterial growth; hence a volume of 10 µl naringenin, dissolved in 99% methanol, was used, 
which contained methanol at a concentration of 5%. The experimental wells each contained 
10 µl naringenin, 20 µl antibiotic, 70 µl fresh TSB and 100 µl of bacterial culture in triplicate 
for each antibiotic and each bacterial strain. The control wells contained; 10 µl 99% methanol 
plus 90 µl TSB for the methanol control, 20 µl antibiotic plus 80 µl TSB for the antibiotic 
control, 10 µl naringenin plus 90 µl TSB for the naringenin control and the bacterial control 
contained 100 µl TSB. Each control well contained 100 µl of the bacterial strains, and this 
was done in triplicate and each well had a final volume of 200µl. A TSB control was also 
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included, containing 100 µl of TSB in triplicate. The plates were then sealed and incubated at 
37ºC with shaking for 18 hours and then read at 620nm in a plate reader. 
For the combinations studies, two concentrations for each of the antibiotics were 
chosen, set at 0.03125 and 0.0625 µg/ml for ampicillin, and 0.25 µg/ml and 1 µ/ml, for 
tetracycline. At these concentrations, the percentage of bacterial growth was high enough to 
show any synergy that might be present after combining the antibiotic and flavonoid. 
Methanol was the solvent of choice for naringenin as it could not dissolve in distilled 
water. 40 mg of naringenin was weighed and dissolved in 1 ml of 99% methanol. The first 
three wells contained 140 µl of TSB while the others contained 80 µl of TSB. 20 µl of 
naringenin was then added to the first three wells and then serially diluted into the remaining 
wells. This ensured that naringenin was at a concentration ranging from 0.02 mg/ml to 2 
mg/ml and methanol at a concentration of 5% that did not affect the bacterial growth. 20 µl of 
the antibiotics at the different concentrations was then added to the wells followed by 100µl 
of the two bacterial strains as outlined earlier. Control wells contained; 10 µl methanol plus 
90 µl TSB, 20 µl antibiotic plus 80 µl TSB, 10 µl naringenin plus 90 µl TSB all containing 
100µl of each of the bacterial strains as outlined earlier. Bacterial controls contained 100 µl 
of each of the bacterial strains plus 100 µl of TSB. The TSB control contained 100 µl of TSB. 
These were also all done in triplicate and each well had a final volume of 200 µl. The 96 well 
microtitre plates were then sealed and incubated at 37ºC with shaking for 18 hours and then 
read at 620 nm in a plate reader. 
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2.3.4. Data analysis 
The synergy ratios (SR) for the concentrations used in the combination studies were 
calculated using the Abbott formula %Cexp=A+B – (AB/100). Where, A was the control level 
of the antibiotic, B the control level of naringenin and Cexp represented the expected efficacy 
of the mixture (naringenin and antibiotic combination) (Levy, Benderly et al. 1986). After 
calculating the %Cexp (expected efficacy), the SR was obtained using the formula SR=Cobs/ 
Cexp, with Cobs representing the observed efficacy. The ratios obtained after these calculations 
were made enabled the determination of what synergistic interaction was present in the 
mixture. If the SR is greater than 1.5, then synergistic interactions are present, if between 0.5-
1.5 then there is an additive effect and if the SR is below 0.5, then the effect is antagonistic 
(Gisi, Binder et al. 1985; Gisi 1996). This enabled the evaluation of the level of 
interaction/association of naringenin and antibiotics. The results outlined were obtained after 
all these parameters were taken into account.  
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2.4.  RESULTS 
2.4.1. Antimicrobial susceptibility testing 
Methicillin, tetracycline, ampicillin and vancomycin were used in the disk diffusion 
susceptibility test including the flavonoids chrysin, naringenin and 7-hydroxyflavone on their 
own as well as in combination. For the microtitre assay, tetracycline and ampicillin were the 
antibiotics of choice and naringenin was the flavonoid used, on their own and in combination. 
The results for both assays are described below. 
 
2.4.1.1. Disk diffusion susceptibility test (Kirby-Bauer assay) 
 
Table 2.1 shows the zones of inhibition interpretive standards for interpreting the zone 
diameters for tetracycline, ampicillin, methicillin and vancomycin, as outlined by the CLSI. 
This was done in order to establish if the bacteria were resistant, intermediate or sensitive to 
the antibiotics at the concentrations used. 
  Zone diameters to the nearest whole mm  
Antibiotic (Concentration) Resistant Intermediate Susceptible/sensitive 
Tetracycline  (30µg/ml) ≤14 15-18 ≥19 
Ampicillin     (10µg/ml) ≤28 ─ ≥29 
Methicillin     (5µg/ml) ≤9 10-13 ≥14 
Vancomycin  (30µg/ml) ─ ─ ≥15 
Table 2.1. Zone Diameter Interpretive (mm) Standards for Staphylococcus species. 
 
 
 
 
 
                                                                                                                                                                                       Chapter 2 
83 
 
 
 
 
Figure 2.1 shows TSA plates containing tetracycline and ampicillin at concentrations 
of 12, 25 and 50 µg/ml. The zones of inhibition at different antibiotic concentrations against 
MSSA ATCC 25923 and MRSA ATCC 33591 strains are outlined in Table 2.2. Ampicillin 
had the largest zones of inhibition with corresponding zone sizes of 31 to 46 mm against 
MSSA ATCC 25923. However, MRSA ATCC 33591was resistant to ampicillin at the same 
concentrations, with small zones (11 mm) of inhibition observed. MSSA ATCC 25923 was 
also susceptible to tetracycline at concentrations of 12, 25 and 50 µg/ml with zones of 
inhibition sizes of 21, 23 and 26 mm respectively. MRSA ATCC 33591 was resistant (0-10 
mm ) to tetracycline concentrations (1,25-50 µg/ml).  
 
 
Figure 2.1. TSA plates with disks containing tetracycline and ampicillin at concentrations of 12, 25 and 50 µg/ml 
against MSSA (ATCC 25923) and MRSA (ATCC 33591) strains. (A) tetracycline against  MSSA (ATCC 25923) 
(B) tetracycline against  MRSA (ATCC 33591) (C) ampicillin against  MSAA (ATCC 25923) (D) ampicillin 
against MRSA (ATCC 33591). 
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MSSA ATCC 25923 was susceptible to; tetracyc 
                                             Inhibition Zone diameter (mm) 
Concentration (µg/ml) Tetracycline Ampicillin Vancomycin Methicillin 
MSSA (ATCC 25923) 
1.25 15.3 ± 1.2 
       (I) 
10 ± 0 
       (R) 
10 ± 0 
        0 
   ─ (R) 
2.5 16.6 ± 0.5 
       (I) 
19 ± 0.9 
       (R) 
12 ± 0 
        0 
13 ± 1.2 
      (I) 
5 20 ± 0 
       (S) 
31 ± 1.2 
       (S) 
14 ± 0.5 
        0 
19 ± 0.9 
       (S) 
12 21 ± 0.5 
       (S) 
37 ± 0.5 
       (S) 
15 ± 0.9 
       (S) 
24 ± 1.7 
       (S) 
25 23 ± 0 
       (S) 
42 ± 0 
       (S) 
16 ± 0.5 
       (S) 
27 ± 2.1 
       (S) 
50 26 ± 0.9 
       (S) 
46 ± 0.5 
       (S) 
17 ± 1.2 
       (S) 
35 ± 1.9 
       (S) 
MRSA (ATCC 33591) 
1.25     ─ (R) 11 ± 0.5 
       (R) 
10 ± 0 
        0 
    ─ (R) 
2.5     ─ (R) 11 ± 0 
       (R) 
12 ± 0.4 
        0 
    ─ (R) 
5     ─ (R) 11 ± 0.5 
       (R) 
14 ± 0.4 
        0 
    ─ (R) 
12     ─ (R) 11 ± 0 
       (R) 
15 ± 0.2 
       (S) 
    ─ (R) 
25     ─ (R) 
 
11 ± 0.5 
       (R) 
17 ± 0.2 
       (S) 
    ─ (R) 
50    10 ± 0 
       (R) 
12 ± 0 
       (R) 
18 ± 0.8 
       (S) 
    ─ (R)  
Diameter of zones of inhibition, including diameter of disk, expressed as means of three replicates; S- susceptible, I- moderate 
susceptible (intermediate), R- resistant, 0- no given values (as outlined by the CLSI).  ─: no zones of inhibition (equivalent to no 
inhibitory effect). Values are expressed as mean ± standard deviation. 
Table 2.2. Inhibition zones (mm) of antibiotics against MSSA ATCC 25923 and MRSA (ATCC 33591) 
strains. 
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MSSA ATCC 25923 was susceptible to; tetracycline at concentrations of 5 to 50 
µg/ml with zones of inhibition of 20 to 26 mm, with concentrations of 1.25 and 2.5 µg/ml 
showing intermediate results with zones of 15.3 and 16.6 mm respectively; ampicillin at 
concentrations of 5 to 50 µg/ml with zones of inhibition of 31 to 46 mm; vancomycin at 
concentrations of 12 to 50 µg/ml with zones of inhibition of 15 to 17 mm and methicillin at 
concentrations of 5 to 50 µg/ml with zones of inhibition of 19 to 35 mm. MRSA ATCC 
33591 was resistant to all antibiotics except vancomycin, which it showed susceptibility to at 
concentrations of 12 to 50 µg/ml with zones of inhibition of 15 to 18 mm. Different 
concentrations of chrysin, naringenin and 7-hydroxyflavone including the DMSO control did 
not show any inhibitory effect on the bacterial growth as no zones of inhibition were 
observed on the TSA plates (Appendix I). Combinations of chrysin, naringenin and 7-
hydroxyflavone with the four antibiotics did not increase or decrease the sizes of the initial 
inhibition zones of the antibiotics (Appendix I).  
 
2.4.1.2. Microdilution susceptibility test (Microtitre assay) 
Table 2.3 represents the MIC interpretive standards for Staphylococcus species as 
outlined by the CLSI. 
 
 
                                                                                                         
                                                MIC (µg/ml) 
 
Antibiotic Susceptible/sensitive Intermediate Resistant 
Tetracycline ≤4 8 ≥16 
Ampicillin ≤0.25 ─ ≥0.5 
 
 Table 2.3. MIC (µg/ml) Interpretive Standards for Staphylococcus spp. 
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The MIC interpretive standards were used to compare the MICs of tetracycline and 
ampicillin in the microtitre assay. The MICs of the antibiotics were obtained by serially 
diluting the antibiotics and ensuring that the ranges were within those outlined by the CLSI. 
Figures 2.2, 2.3 and 2.4 below, show the bacterial growth of MSSA ATCC 25923 and MRSA 
ATCC 33591 in different tetracycline, ampicillin and naringenin concentrations. The 
concentrations of tetracycline and ampicillin chosen for the combination studies with 
naringenin were those that showed little or no inhibitory effect on the bacterial growth. This 
enabled any synergistic or additive effect that naringenin would have to be measurable, as 
any reduction in the bacterial growth rate at these concentrations would definitely have been 
as a result of naringenin. 
 
 
 
According to the CLSI MIC interpretive standards the MICs for tetracycline are ≤4 
and ≥6 µg/ml for sensitivity and resistance respectively. The tetracycline concentrations used 
Figure 2.2. Effect of minimum inhibitory concentrations (MICs) of tetracycline on the bacterial growth of MSSA 
ATCC 25923 and MRSA ATCC 3359. Bacterial growth is expressed as means of three replicates and values are 
stated as means ± standard deviation. 
 
 
 
 
                                                                                                                                                                                       Chapter 2 
87 
 
ranged from 0.0625 to 32 µg/ml (Figure 2.2). The bacterial growth controls for the MSSA 
ATCC 25923 and MRSA 33591 strains were 95 and 94% respectively. In this study, MSSA 
ATCC 25923 showed a bacterial growth rate of between 84 to 88% at concentrations of 2 to 
32 µg/ml (showing a 7 to 11% reduction in bacterial growth rate when compared to the 
bacterial control), whereas MRSA ATCC 33591 had a bacterial growth rate of 94 to 95% at 
the same concentrations. MSSA ATCC 25923 showed a bacterial growth rate decrease from 
91% at 1 µg/ml to 84% at 32 µg/ml (the highest concentration used). The MRSA ATCC 
33591 strain showed resistance to tetracycline even at the highest concentration used (32 
µg/ml). The concentrations chosen for the combination studies were 0.25 and 1 µg/ml which 
had bacterial growth rates of 94 and 91% respectively, for MSSA ATCC 25923 and bacterial 
growth rates of 95 and 96% for MRSA ATCC 33591 respectively. 
 
 
 
 
Figure 2.3. Effect of minimum inhibitory concentrations (MICs) of ampicillin on the bacterial growth of 
MSSA ATCC 25923 and MRSA ATCC 3359. Bacterial growth is expressed as means of three replicates 
and values are stated as means ± standard deviation.   
 
Ampicillin 
 
Ampicillin 
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The MICs for ampicillin are ≤ 0.25 and ≥ 0.5 µg/ml, for sensitivity and resistance, as 
outlined by the CLSI. The bacterial controls had bacterial growth rates of 95 and 94% for 
MSSA ATCC 25923 and MRSA ATCC 33591 strains respectively (Figure 2.3). In this study, 
0.125 and 0.5 µg/ml ampicillin showed an 80% bacterial growth rate for the MSSA ATCC 
25923 strain (showing a 15% reduction in bacterial growth rate) compared to the MRSA 
ATCC 33591 that showed a bacterial growth rate of about 95% at the same concentrations. 
At 0.25 and 1 µg/ml ampicillin, the bacterial growth rate was 88 and 82% respectively 
(showing a 7 to 13% reduction in bacterial growth rate). The bacterial growth rate for the 
MSSA ATCC 25923 strain decreased from 91% at 0.015625 µg/ml, to 80% at 0.125 µg/ml 
ampicillin. The MRSA ATCC 33591 strain was resistant to ampicillin at all concentrations 
used. The ampicillin concentrations chosen for the combination studies, with naringenin, 
were 0.03125 and 0.0625 µg/ml which both had bacterial growth rates of about 90 and 96%, 
for MSSA ATCC 25923 and MRSA ATCC 33591 respectively. 
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Figure 2.4 shows results obtained after different naringenin concentrations were tested 
against MSSA ATCC 25923 and MRSA ATCC 33591 strains. The bacterial controls had 
bacterial growth rates of 95 and 94% for MSSA ATCC 25923 and MRSA ATCC 33591 
respectively. Naringenin showed minimal inhibitory effect on the bacterial growth rate 
(which remained unchanged between 90 and 95%) for both strains at concentrations between 
0.002 and 0.063 mg/ml naringenin. The bacterial growth rate was then reduced from 94%, at 
0.063 mg/ml naringenin, to 88 and 78% at naringenin concentrations of 0.25 and 0.5 mg/ml 
respectively. 1 and 2 mg/ml naringenin had a bacterial growth rate of 86 and 89% 
Figure 2.4. Effect of different naringenin concentrations on the bacterial growth of MSSA ATCC 25923 and 
MRSA ATCC 3359. Bacterial growth is expressed as means of three replicates and values are stated as means 
± standard deviation.  
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respectively for the MSSA ATCC 25923 strain. The MRSA ATCC 33591 strain was resistant 
to naringenin at concentrations of 0.002 to 0.125 mg/ml with bacterial growth rates of 94%. 
The bacterial growth rate decreased to 90 and 86% at concentrations of 0.25 to 1 mg/ml 
respectively, with 2 mg/ml showing a bacterial growth rate of 89%. The same range of 
naringenin concentrations were selected for the combination studies with tetracycline and 
ampicillin. 
 
 
As described in Figure 2.2, tetracycline had bacterial growth rates of 91 and 95% for 
MSSA ATCC 25923 and MRSA ATCC 33591 respectively at a concentration of 1 µg/ml. 
The bacterial, antibiotic, naringenin and methanol controls had bacterial growth rates of 94, 
                            
    MSSA ATCC 25923                                            MRSA ATCC 33591 
Tetracycline (1 
µg/ml) + naringenin 
(mg/ml) 
Concentration 
Bacterial 
cell growth 
(%) 
Synergy 
ratio (SR) 
Interpretation  Bacterial 
cell growth 
(%) 
Synergy 
ratio (SR) 
Interpretation 
0.004 90 0.91 Add  95 0.96 Add 
0.008 89 0.90 Add  94 0.95 Add 
0.016 89 0.90 Add  95 0.96 Add 
0.031 89 0.90 Add  95 0.96 Add 
0.063 87 0.88 Add  95 0.96 Add 
0.125 85 0.86 Add  94 0.95 Add 
0.25 85 0.86 Add  88 0.89 Add 
0.5 89 0.90 Add  91 0.92 Add 
1 89 0.90 Add  92 0.93 Add 
2 90 0.91 Add  91 0.92 Add 
Table 2.4. Antibacterial activity of naringenin (0.004 to 2 mg/ml) in combination with tetracycline 
(1µg/ml) against MSSA ATCC 25923 and MRSA ATCC 33591. 
 
 
 
 
                          Staphylococcus aureus 
                            ATCC 25923                                                             ATCC 33591 
Tetracycline (0.5 
µg/ml) + naringenin 
(mg/ml) 
Concentration 
Bacterial cell 
growth (%) 
Synergy 
ratio (SR) 
Interpretation Bacterial cell 
growth (%) 
Synergy 
ratio (SR) 
Interpretation 
0.004 92 0.93 Add 94 0.94 Add 
0.008 92 0.93 Add 95 0.95 Add 
0.016 92 0.93 Add 95 0.95 Add 
0.031 92 0.93 Add 95 0.95 Add 
0.063 90 0.91 Add 95 0.95 Add 
0.125 88 0.89 Add 94 0.94 Add 
0.25 87 0.88 Add 92 0.92 Add 
0.5 85 0.86 Add 91 0.91 Add 
1 90 0.91 Add 94 0.94 Add 
2 91 0.92 Add 93 0.93 Add 
 Table 2.4. Effect of naringenin (0.004 to 2 µg/µl) on the MIC of tetracycline (1µg/µl) against MSSA 
(ATCC 25923) and MRSA (ATCC 33591) strains. 
 
 
 
Add- Additive effect  
 
ATCC 25923; Bacterial 
control-94%, antibiotic 
control-90%, naringenin 
control-90% and 
met anol control-93%.                
ATCC 33591; Bacterial 
control-95%, antibiotic 
control-94%, naringenin 
control-90% and 
methanol control-94%.                  
Add- Additive effect 
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90, 90 and 93% for MSSA ATCC 25923 and 95, 94, 90 and 94% for MRSA ATCC 33591 
respectively. Table 2.4 shows that the combination of tetracycline with naringenin at 0.125 
and 0.25 µg/ml against MSSA ATCC 25923, reduced the bacterial growth rate from 91% to 
85% (6% reduction in bacterial growth rate) when compared to tetracycline used on its own. 
Nonetheless, MRSA ATCC 33591 showed a reduction in bacterial growth rate to 88% at 0.25 
mg/ml naringenin and tetracycline combination (7% reduction in bacterial growth rate), while 
tetracycline on its own had a bacterial growth rate of 95% at 1 µg/ml (Figure 2.2). The 
synergistic calculations confirmed these results between naringenin and tetracycline as 
showing additive effects, meaning that naringenin did enhance the antibacterial activity of 
tetracycline. 
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As outlined earlier (Figure 2.2), tetracycline had bacterial growth rates of 94% for 
both MSSA ATCC 25923 and MRSA 33591 at a concentration of 0.25 µg/ml. The bacterial, 
antibiotic, naringenin and methanol controls had bacterial growth rates of 94, 93, 91 and 93% 
for MSSA ATCC 25923 and 95, 95, 91 and 95% for MRSA ATCC 33591 respectively. Table 
2.5 showed that the combination of 0.25 µg/ml tetracycline with naringenin at 0.125, 0.25 
and 0.5 µg/ml against MSSA ATCC 25923 resulted in bacterial growth rates of 88 and 84% 
respectively (a bacterial growth reduction of 6 to 10%), when compared to tetracycline on its 
own. However, MRSA ATCC 33591 showed an 87 and 89% bacterial growth rate at 
naringenin concentrations of 0.25 and 0.5 mg/ml in combination with 0.25 µg/ml tetracycline 
(5 to 7% reduction in bacterial growth rate), while tetracycline on its own had a bacterial 
  
            MSSA ATCC 25923 
   
             MRSA ATCC 33951  
Tetracycline (0.25 
µg/ml) + naringenin 
(mg/ml) 
Concentration 
Bacterial 
cell growth 
(%) 
Synergy 
ratio (SR) 
Interpretation   Bacterial 
cell growth 
(%) 
Synergy 
ratio (SR) 
Interpretation 
0.004 92 0.93 Add   95 0.95 Add 
0.008 92 0.93 Add   95 0.95 Add 
0.016 92 0.93 Add   95 0.95 Add 
0.031 92 0.93 Add   95 0.95 Add 
0.063 91 0.92 Add   94 0.94 Add 
0.125 88 0.89 Add   94 0.94 Add 
0.25 84 0.85 Add   89 0.89 Add 
0.5 84 0.85 Add   87 0.87 Add 
1 90 0.91 Add   93 0.936 Add 
2 90 0.91 Add   92 0.92 Add 
Table 2.5. Antibacterial activity of naringenin (0.004 to 2 mg/ml) in combination with tetracycline (0.25 
µg/ml) against MSSA ATCC 25923 and MRSA ATCC 33591 strains. 
 
Table 2.6. Effect of naringenin (0.004 to 2 µg/µl) on the MIC of tetracycline (0.25 µg/µl) against MSSA 
(ATCC 25923) and MRSA (ATCC 33591) strains. 
Add- Additive effect 
 
 
ATCC 25923; Bacterial control-
93%, antibiotic control-90%, 
naringenin control-91% and 
methanol control-92%.                 
ATCC 33591; Bacterial control-
94%, antibiotic control-93%, 
naringenin control-93% and 
methanol control-93%.                   
Add- Additive effect 
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growth rate of 94% at 0.25 µg/ml. The synergistic calculations confirmed these results 
between naringenin and tetracycline as showing additive effects, meaning that naringenin did 
enhance the antibacterial activity of tetracycline.  
.  
 
 
Table 2.6 shows the combination of 0.0625 µg/ml ampicillin with 0.004 to 2 mg/ml 
naringenin. As outlined in Figure 2.3, ampicillin produced bacterial growth rates of 90 and 
96%, for MSSA ATCC 25923 and MRSA ATCC 33591 respectively, at a concentration of 
0.0625 µg/ml. The bacterial, antibiotic, naringenin and methanol controls had bacterial 
growth rates of 94, 90, 90 and 93% for MSSA ATCC 25923 and 95, 93, 92 and 94% for 
 
                                  MSSA ATCC 25923                                              MRSA ATCC 33591 
Ampicillin (0.0625 
µg/ml) + naringenin 
(mg/ml) 
Concentration 
Bacterial 
cell growth 
(%) 
Synergy 
ratio (SR) 
Interpretation  Bacterial 
cell growth 
(%) 
Synergy 
ratio (SR) 
Interpretation 
0.004 86 0.87 Add  95 0.96 Add 
0.008 85 0.86 Add  94 0.95 Add 
0.016 86 0.87 Add  95 0.96 Add 
0.031 82 0.83 Add  95 0.96 Add 
0.063 72 0.73 Add  95 0.96 Add 
0.125 69 0.67 Add  93 0.94 Add 
0.25 73 0.74 Add  89 0.90 Add 
0.5 83 0.84 Add  91 0.92 Add 
1 82 0.83 Add  92 0.93 Add 
2 88 0.89 Add  89 0.90 Add 
Table 2.6. Antibacterial activity of naringenin (0.004 to 2 mg/ml) in combination with ampicillin 
(0.0625µg/ml) against MSSA ATCC 25923 and MRSA ATCC 33591 strains. 
 
 
Table 2.7. Effect of naringenin (0.004 to 2 mg/ml) on the MIC of ampicillin (0.0625µg/ml) against MSSA 
(ATCC 25923) and MRSA (ATCC 33591) strains. 
 
Add- Additive effect  
 
ATCC 25923; Bacterial 
control-94%, antibiotic 
control-90%, naringenin 
control-90% and 
methanol control-93%.                
ATCC 33591; Bacterial 
control-95%, antibiotic 
control-94%, naringenin 
control-90% and 
methanol control-94%.                  
Add- Additive effect 
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MRSA ATCC 33591 respectively. The study showed that 0.0625 µg/ml ampicillin combined 
with 0.063, 0.125 and 0.25 mg/ml naringenin yielded bacterial growth rates of 72, 69 and 
73% respectively, for the MSSA ATCC 25923 strain, compared to the bacterial growth rate 
of 90% at 0.0625 µg/ml ampicillin (with a reduction of bacterial growth rate of as high as 
21% at 0.125 mg/ml naringenin). The MRSA ATCC 33591 strain had a bacterial growth rate 
of 89% at 0.25 and 2 mg/ml naringenin combined with 0.0625 µg/ml ampicillin. The 
synergistic calculations confirmed these results between naringenin and ampicillin as 
showing additive effects, meaning that naringenin did enhance the antibacterial activity of 
ampicillin. 
 
                             
 MSSA ATCC 25923                                                             MRSA ATCC 33591 
Ampicillin 
(0.03125 µg/ml) 
+ naringenin 
(mg/ml) 
Concentration 
Bacterial 
cell 
growth 
(%) 
Synergy 
ratio 
(SR) 
Interpretation  Bacterial cell 
growth (%) 
Synergy 
ratio 
(SR) 
Interpretation 
0.004 89 0.90 Add  94 0.94 Add 
0.008 90 0.91 Add  94 0.94 Add 
0.016 90 0.91 Add  94 0.94 Add 
0.031 90 0.91 Add  94 0.94 Add 
0.063 90 0.91 Add  94 0.94 Add 
0.125 86 0.87 Add  92 0.92 Add 
0.25 76 0.77 Add  92 0.92 Add 
0.5 77 0.78 Add  89 0.89 Add 
1 86 0.87 Add  92 0.92 Add 
2 86 0.87 Add  93 0.93 Add 
 
Table 2.7. Antibacterial activity of naringenin (0.004 to 2 mg/ml) in combination with ampicillin 
(0.03125µg/ml) against MSSA ATCC 25923 and MRSA ATCC 33591 strains. 
 
 
Table 2.7. Effect of naringenin (0.004 to 2 mg/ml) on the MIC of ampicillin (0.0625µg/ml) against MSSA 
(ATCC 25923) and MRSA (ATCC 33591) strains. 
 
Add- Additive effect 
 
 
ATCC 25923; Bacterial control-
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Table 2.7 shows the combination of 0.03125 µg/ml ampicillin with 0.004 to 2 mg/ml 
naringenin. As outlined in Figure 2.3, ampicillin produced bacterial growth rates of 90 and 
96% at a concentration of 0.03125 µg/ml. The bacterial, antibiotic, naringenin and methanol 
controls had bacterial growth rates of 93, 90, 91 and 92% for MSSA ATCC 25923 and 94, 
93, 93 and 93% for MRSA ATCC 33591 respectively. The study showed that 0.03125 µg/ml 
ampicillin combined with 0.125, 0.25 and 0.5 mg/ml naringenin, yielded bacterial growth 
rates of 86, 76 and 77% respectively, compared to the bacterial growth rate of 90% at 
0.03125 µg/ml ampicillin alone. The MRSA ATCC 33591 strain had a bacterial growth rate 
of 89% at 0.5 mg/ml naringenin combined with 0.0625 µg/ml ampicillin. The calculated 
synergistic ratios confirmed these results between naringenin and ampicillin as being additive 
effects, meaning that naringenin did enhance the antibacterial activity of ampicillin. 
 
2.5. DISCUSSION 
In the disk diffusion assay, the antibiotics showed remarkable antimicrobial activity 
with ampicillin producing the largest inhibition zones for MSSA ATCC 25923. Tetracycline 
had zones that ranged from 10 to 26 mm, vancomycin 10 to 17 mm and methicillin 13 to 35 
mm for MSSA ATCC 25923 with the largest zones corresponding to the highest 
concentration. Vancomycin was the only antibiotic that had similar inhibition zone sizes for 
both strains showing that MRSA ATCC 33591 was susceptible to it with the greatest effect 
seen at concentrations of 12, 25 and 50 µg/ml. Tetracycline and methicillin did not have any 
inhibitory effect on MRSA ATCC 33591 as no inhibition zones were present. Ampicillin had 
small zones of 12 mm, which was not considered an inhibitory effect. Chrysin, naringenin 
and 7-hydroxyflavone did not have any inhibitory effect on bacterial growth at any of the 
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concentrations used as observed by the absence of inhibition zones on the TSA plates for 
both MRSA ATCC 33591 and MSSA ATCC 25923. 
Combination studies with the disk diffusion assay revealed that the flavonoids did not 
enhance the antibacterial activity of the antibiotics. DMSO used as the solvent for the disk 
diffusion assay did not have any effect on bacterial growth even at a 100% concentration 
when loaded onto the disk despite reports that it has some antimicrobial activity (Dayang, 
Noraziah et al. 2008). It has been shown that flavonoids may diffuse out of the disks, used in 
the disk diffusion assay, at a low rate thereby affecting their antibacterial activities (Zheng, 
Tan et al. 1996). This could explain why the flavonoids did not seem to have any inhibitory 
effect either on their own or in combination with the different antibiotics.  
Naringenin was the flavonoid of choice for the microtitre assay. Chrysin and 7-
hydroxyflavone were not included as they precipitated and formed suspensions when diluted 
in the solvent. This precipitation would have affected the level of contact of the bacterial cells 
with the flavonoid and consequently the antibiotic during combination studies. The 
precipitation could have resulted in interpreting it as false negative since the precipitation 
would have been misinterpreted as bacterial growth. The solvent of choice for naringenin was 
methanol as it dissolved without precipitating. DMSO was not used as a solvent because it 
was observed that it had some effect on the bacterial growth when used in the microtitre 
assay. Methanol was used at a 5% concentration to ensure that it did not have any effect on 
bacterial growth. Distilled water was the solvent used for the antibiotics. MSSA ATCC 
25923 was susceptible to both tetracycline and ampicillin at MICs of ≤ 4 µg/ml and ≤ 0.25 
µg/ml respectively, as illustrated by the MIC interpretive standards outlined by the CLSI. 
MRSA ATCC 33591 showed a consistent rate of resistance against the bacterial growth for 
both antibiotics.  
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The two concentrations chosen for the combination studies were 0.25 and 1µg/ml for 
tetracycline and 0.03125 and 0.0625 µg/ml for ampicillin. Bacterial growth at these 
concentrations was high enough to demonstrate inhibitory effects naringenin would have in 
the combination studies. This was essential in establishing and classifying the effect as being 
synergistic, additive or antagonistic. Naringenin was used at concentrations ranging from 
0.002 to 2 mg/ml. Naringenin concentrations of 0.125, 0.25 and 0.5 mg/ml enhanced the 
antibacterial activity of 0.25 and 1 µg/ml tetracycline against MSSA ATCC 25923 and 
MRSA ATCC 33591. In the case of ampicillin, naringenin concentrations of 0.063, 0.0125, 
0.25 and 0.5 µg/ml enhanced antibacterial activity against both strains.  
Numerous studies have been carried out that highlight the beneficial properties of 
flavonoids. However, acylated flavonoids are rather new, therefore, only a limited amount of 
scientific information is available (Gatto, Falcocchio et al. 2002; Celiz, Audisio et al. 2010; 
Celiz, Daz et al. 2011). Naringenin is a flavonone mainly found in citrus fruits and possesses 
phytochemical properties (van Acker, Hulshof et al. 2001; Lee, Lee et al. 2011). It has been 
shown to inhibit bacterial motility proving that it is capable of interfering with the proton 
motive force (Cushnie and Lamb 2005). A study on the effect of naringenin on lung 
metastasis showed that it reduced the incidence and number of lung metastatic colonies (Qin, 
Jin et al. 2011). Another study also revealed that naringenin showed a higher antibacterial 
effect compared to other flavones (Nur, Noraziah et al. 2012). Studies have reported that 
structural changes in the flavonoids aids in the acquisition of antimicrobial activities. The 
addition of two or three extra hydroxyl groups at positions 7, 2´ and 4´ to 5-
hydroxyflavanones  and 5-hydroxyisoflavanones inhibited Streptococcus mutans and 
Streptococcus sobrinus growth using the disk diffusion assay (Osawa, Yasuda et al. 1992). 3-
hydroxy, 5-hydroxy and 7-hydroxyflavones have also been shown to have antioxidant 
properties (Firuzi, Mladenka et al. 2004; Firuzi, Lacanna et al. 2005). Tsuchiya and 
 
 
 
 
                                                                                                                                                                                       Chapter 2 
98 
 
colleagues (1996) demonstrated that 2´,4´- or 2´,6´-dihydroxylation of the B ring and 5,7-
dihydroxylation of the A ring in the flavanone structure played a critical role in rendering the 
anti-MRSA flavonoid ability (Tsuchiya, Sato et al. 1996). Chrysin has numerous beneficial 
properties such as antioxidant, anti-inflammatory, anti-diabetogenic, anti-hypertensive and 
axiolytic properties (Tahir and Sultana 2011). Studies have also shown that sub-inhibitory 
concentrations of chrysin are capable of preventing the production of α-hemolysin (pore-
forming toxin responsible for tissue damage) by S. aureus (Wang, Qiu et al. 2011). 
Antibacterial activities of plant flavonoids against MRSA have generated a lot of 
interest (Tsuchiya, Shimizu et al. 1985; Xu and Lee 2001; Nanayakkara, Burandt et al. 2002; 
Nishida and Satoh 2004). Several studies have also demonstrated the synergistic effects of 
plant extracts with various antibiotics and a subsequent reduction in the MIC of the 
antibiotics against some resistant bacterial strains including S. aureus (Darwish, Aburjai et al. 
2002; Stapleton, Shah et al. 2004; Braga, Leite et al. 2005; Fadli, Saad et al. 2012). 
Combination studies demonstrated the synergistic effect of flavonoids, such as 6, 7-
dihydroxyflavone and isoflavanone with antibiotics oxacillin and mupirocin against MRSA 
(Shirataki, Wakae et al. 2004; Sato, Tanaka et al. 2006). It is believed that the mechanism of 
antibacterial action may be as a result of the flavonoid being able to reverse bacterial 
resistance to β-lactam antibiotics (Eumkeb, Siriwong et al. 2012). Synergistic interactions 
between propolis and tetracycline (Mirzoeva, Grishanin et al. 1997) as well as amipicillin 
(Stepanovic, Antic et al. 2003) have also been documented. Synergistic interactions between 
pentacyclic triterpenoids and antibiotics such as methicillin and vancomycin have also been 
reported (Chung, Navaratnam et al. 2011).  
Africa can be a source of therapeutically useful botanical antimicrobial compounds. 
Further studies can be initiated on medicinal plants especially in combination with 
antimicrobial agents. Medicinal plants and plant compounds have been used in a number of 
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cultures to treat various infections and it is for this reason that studies are being done to 
screen them for antimicrobial activities in the hope of administering them in combination 
with antibiotics (Betoni, Mantovani et al. 2006; Chung, Navaratnam et al. 2011; Stefanovic, 
Stanojevic et al. 2012). Investigating plant extracts through structural alterations may pave 
the way for the development of pharmacologically acceptable antimicrobial agents. However, 
the MICs of plant derived antimicrobial compounds are more elevated than those of fungal or 
bacterial produced antibiotics and this tends to limit their therapeutic use (Gibbons, Moser et 
al. 2004). Antibiotic resistance still remains a global problem and the search for solutions still 
remains a challenge, hence the need to focus on other ways to manage these infections. 
Further studies on the interactions between flavonoids and antibiotics is one way in which 
multidrug resistance mechanism of bacteria can be overcome (Braga, Leite et al. 2005; 
Herath, Mikell et al. 2006; Celiz, Daz et al. 2011; Wang, Qiu et al. 2011).  
This study showed that naringenin enhanced the antibacterial activities of tetracycline 
and ampicillin, in the microtitre assay, at concentrations that initially did not have any effect 
on bacterial growth. However, naringenin, chrysin and 7-hydroxyflavone did not enhance the 
antibacterial activities of the antibiotics in the disk diffusion assay, which led to the 
conclusion that the poor and/or slow diffusion of the flavonoids from the disks may have 
been a contributing factor. Future prospects will involve using different concentrations and 
types of flavonoids, in combination with various antibiotics, to challenge S. aureus and 
analyze the effect at a molecular level. The efflux pump genes of S. aureus can also be 
analyzed to assess which ones may be up/down regulated in the presence of these 
compounds.  
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methicillin-sensitive and methicillin-resistant Staphylococcus 
aureus using Polymerase Chain Reaction (PCR) 
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3.1.  ABSTRACT 
Efflux pump proteins are expressed in both antibiotic-susceptible and antibiotic-
resistant bacteria. Efflux pumps are transport proteins responsible for the extrusion of toxic 
substances, including a number of antibiotics, from inside the bacterial cell to the external 
environment. These efflux mechanisms have been widely identified as major and important 
components in rendering bacteria resistant to many classes of antibiotics. Whereas certain 
efflux pumps are capable of expelling a number of different antibiotics (referred to as 
multidrug resistance (MDR) pumps), others are antibiotic-specific. A number of efflux pump 
genes have been identified in Staphylococcus aureus and these have been shown to play a 
role in conferring resistance to many different antibiotics. 
In this study, three efflux pump genes - mepA, sepA and gyrA - were analyzed using 
Polymerase Chain Reaction (PCR); 16S was included as a positive control. The aim of the 
study was to determine which of the three genes were present or absent in methicillin-
sensitive and methicillin-resistant S. aureus strains MSSA ATCC 25923 and MRSA ATCC 
33591, respectively. The results showed the presence of the mepA and gyrA in both MSSA 
ATCC 25923 and MRSA ATCC 33591 strains. However sepA was only present in the 
MRSA ATCC 33591 strain. The presence of mepA and gyrA in both strains suggests that 
possible chromosomal mutations, resulting in their over-expression, may be responsible for 
their role in drug resistance. The presence of sepA MRSA and not MSSA suggested that it 
plays a role in conferring resistance possibly encoding a drug resistant protein. 
 
3.2. INTRODUCTION 
In the last century, a number of measures have been put in place to manage, treat and 
prevent infectious diseases. Antibiotics, in combination with chemical compounds used as 
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disinfectants and antiseptics (also called biocides), have been used to eradicate and manage 
numerous pathogenic bacteria that cause life-threatening conditions (Gilbert and McBain 
2003). Alarmingly, due to the increased use of antibiotics and biocides in the treatment of 
these pathogens, some bacterial strains have developed resistance to one or more classes of 
these antibiotics and biocides, causing concern worldwide (Gilbert and McBain 2003; Orji, 
Nworie et al. 2012). Bacteria develop resistance to antibiotics due to three main strategies, 
which are: drug inactivation by enzymes (Davies 1994), modification of target sites (Spratt 
1994) and extrusion of antibiotics and toxic substances by efflux (Nakaido 1994). 
Staphylococcus aureus (S. aureus) is part of the normal flora found on the skin and 
mucous membranes of the mouth, nose and ears of 20-30% of the human population 
(Peacock, de Silva et al. 2001). Globally, this pathogen is considered to be one of the most 
prevalent and important clinical isolates in humans (Waters, Contente-Cuomo et al. 2011; 
Chuang, Hsiao et al. 2012). Currently, S. aureus is the main pathogen associated with 
community-acquired infections and the use of traditional hospital control measures alone is 
inadequate (Deresinski 2005; Stefani, Chung et al. 2012).  
Methicillin-resistant Staphylococcus aureus (MRSA) was initially identified in the 
1960s, commonly associated with hospitals and healthcare facilities. In Africa, one of the first 
reported cases of MRSA was isolated from clinical samples collected from hospitalized 
African and Indian children in Durban (Scragg, Appelbaum et al. 1978). Subsequently, 
between the mid-1980s and early 1990s, there was a sharp increase in the reports of MRSA 
cases in numerous African countries, including Ethiopia (Geyid and Lemeneh 1991), Kenya 
(Omari, Malonza et al. 1997), Nigeria (Rotimi, Orebamjo et al. 1987; Okesola, Oni et al. 
1999), Senegal (Sow, Wade et al. 1998), South Africa (van den Ende and Rotter 1986; 
Peddie, Donald et al. 1988; Gardee and Kirby 1993) and Sudan (Musa, Shears et al. 1999). 
Also, an increase in MRSA prevalence has been reported in other parts of the world, 
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including several European (Rasmussen, Fowler et al. 2011) and Asian countries such as 
Taiwan (Hsueh, Chen et al. 2002), Japan (Lotus, Imamura et al. 1995) and the Republic of 
Korea (Woojoo and Seunchill 1999).  MRSA causes a wide range of deep tissue infections 
such as osteomyelitis, arthritis, endocarditis and renal and breast abscesses (Daniyan, 
Galadima et al. 2011). It also causes wound, skin and soft tissue infections particularly 
carbuncles, furuncles and scalded skin syndrome (Richards, Edwards et al. 1999a; Richards, 
Edwards et al. 1999b; Perez-Vazquez, Vindel et al. 2009). 
Methicillin-susceptible/sensitive S. aureus (MSSA) usually develop into MRSA by 
acquiring a large DNA fragment, known as staphylococcal chromosomes cassette mec 
(SCCmec) type IV, and inserting it into their genomes (Hiramatsu, Cui et al. 2001; 
Rasmussen, Fowler et al. 2011). The SCCmec contains the methicillin resistant determinant 
gene, mecA, which encodes for a modified penicillin-binding protein (PBP2a) with low 
affinity for β-lactams (Hiramatsu, Cui et al. 2001; Pinho, Filipe et al. 2001; Monecke, 
Coombs et al. 2011; Sanchini, Campanile et al. 2011); PBP2a is essential, as it plays a role in 
cell wall synthesis of the bacteria (Shopsin and Kreiswirth 2001). More recently, however, 
MRSA strains with a modified mecA gene (designated mecALGA251) have been isolated in the 
UK and Denmark among the human and bovine populations. This gene was shown to be only 
70% homologous to the S. aureus mecA (Garcia-Alvarez, Holden et al. 2011).  
Bacteria that have a multidrug-resistant (MDR) phenotype, which are controlled by 
MDR efflux pumps (EPs), create the most concern in the healthcare sector (Costa, Ntokou et 
al. 2010). MDR EPs are cytoplasmic membrane transport proteins found in both Gram-
positive and Gram-negative bacteria. These pumps are able to expel antimicrobial agents of 
different classes, including biocides (Morar and Wright 2010); this ability to extrude these 
various compounds contributes to increased levels of bacterial resistance (Van Bambeke, 
Balzi et al. 2000; Borges-Walmsley, McKeegan et al. 2003; Poole 2005). MDR EPs were 
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first discovered in human cancer cells resistant to fluoroquinolones (Rice 2006). Currently, 
efflux pumps are categorized into five diverse families which are: major facilitator super 
(MFS) family, ATP-binding cassette (ABC) transporters, small multidrug resistance (SMR) 
transporters, multidrug and toxic compound extrusion (MATE) family and resistance-
nodulation-cell division (RND) family (Kaur 2002; Lynch 2006; Morar and Wright 2010; Cui 
and Davidson 2011; He, Thorpe et al. 2011; He, Zhang et al. 2011). To date, a number of 
MDR EPs have been identified in S. aureus which are encoded by either chromosomal-borne 
genes (norA, norB, norC, mepA, sepA and sdrM), or plasmid-borne genes (qacA/B, smr, 
qacG, qacJ and qacH) (Poole 2005; Poole 2007). Typically, whereas chromosomally-
encoded MDR EPs result in reduced susceptibility to both antibiotics and biocides, the 
plasmid-encoded pumps reduce the susceptibility to biocides only (Poole 2007).  
The gyrA and gyrB genes encode subunits of DNA gyrase, which together with the 
enzyme topoisomerase IV, are crucial for bacterial replication (Bates, O'Dea et al. 1996). 
Topoisomerase IV, encoded by grlA and grlB, is believed to be the principle target site for 
fluoroquinolone action (Sreedharan, Oram et al. 1990; Hooper and Wolfson 1991; Goswitz, 
Willard et al. 1992). However, mutations in both the grl and gyr gene loci are usually 
responsible for the quinolone resistance exhibited in S. aureus isolates (Ferrero, Cameron et 
al. 1995). These mutations can consequently result in the continued function of these vital 
bacterial enzymes, even in the presence of normally toxic concentrations of fluoroquinolone 
(Kaatz and Seo 1995).  
The aim of this study was to compare the presence of three EP genes (mepA, sepA and 
gyrA, including the house-keeping gene 16S) in methicillin-sensitive ATCC 25923 (MSSA) 
and methicillin-resistant ATCC 33591 (MRSA) strains using Polymerase Chain Reaction 
(PCR). Optimization of PCR was done by running primer concentration, magnesium chloride 
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(MgCl2) concentration and annealing temperature profiles. Whereas mepA and gyrA were 
identified in both S. aureus strains, sepA was detected in the MRSA ATCC 33591 strain only.  
 
3.3. MATERIALS AND METHODS 
3.3.1. Bacterial strains and growth conditions 
The bacterial isolates used for this analysis were MSSA (ATCC 25923) and MRSA (ATCC 
3359)1 strains obtained from the American Type Culture Collection (ATCC). The bacterial 
isolates were cultured on tryptone soy agar (TSA) (Oxoid Ltd, UK) plates and incubated at 
37ºC, for 16-18 hours. A single colony forming unit (CFU) was inoculated into tryptone soy 
broth (TSB) (Oxoid Ltd, UK) and incubated for 5-8 hours, with shaking, at 37°C to a 
turbidity equivalent to 0.5 McFarland standard (~1 × 10
8 
to 2 × 10
8 
CFU/ml). 
 
3.3.2. Quantification of Total RNA and cDNA concentration 
The quantification of total RNA and cDNA was done using the the Quant-iT
TM
 assay 
system. The working solution was made by diluting the Quant-iT
TM
 reagent, using a 1:200 
ratio, in Quant-iT
TM
 buffer. 200 µl of working solution was required for each sample and 
standard. 199 X n μl of Quant-iTTM buffer was mixed with 1 x n μl of Quant-iTTM reagent 
(where n represents the number of standards plus number of samples) to a make up the 
Quant-iT
TM
 working solution. 10 μl of each standard was added to 190 μl of the working 
solution. Then 180-199 μl of working solution was mixed with 1-20 µl of each sample to 
make up a final volume of 200 μl (Table 3.1).  
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Standard (Assay tubes) Sample (Assay tubes) 
Working solution volume 190 µl 180-199 µl 
Volume of standard 10 µl – 
Volume of sample – 10-20 µl 
Total volume in assay tube 200 µl 200 µl 
 
The tubes were vortexed for 2-3 seconds and incubated at room temperature for 2 
minutes. After calibrating the Qubit® fluorometer with known standards, fluorometer sample 
readings were taken and the concentrations (µg/ml) calculated using the formula:  
Concentration of sample = QF value x 200/X 
Where: 
QF = Qubit® fluorometer reading, 
X= number of µl of sample added. 
 
3.3.3. Total RNA extraction 
Total RNA was extracted from bacterial isolates MSSA ATCC 25923 and MRSA 
ATCC 33591 strains using the SV Total RNA Isolation System (Promega) as per the 
manufacturer’s instructions. Bacterial cultures were grown in tryptone soy broth (TSB) 
overnight with shaking at 37ºC.  
The following day, a 1:50 dilution of the culture was made and grown to an OD600 of 
0.6 (read using a spectrophotometer). 1 ml of culture was then transferred to a 1.5 ml 
Table 3.1. Volumes used in the Qubit® Fluorometer system.  
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microcentrifuge tube and centrifuged at room temperature (r.t) for 2 minutes at 14 000 × g 
(this process was repeated until all the culture was centrifuged). The supernatant was then 
carefully removed and the pellet left as dry as possible. The pellet was resuspended in 100 µl 
freshly prepared TE (Trypsin EDTA) [0.05% trypsin (w/v) and 0.53 mM EDTA dissolved in 
1X PBS] containing 3mg/ml lysozyme and tapped gently to mix. The resuspended pellet was 
incubated at room temperature for 3-5 minutes. 175 µl RNA Lysis Buffer [4M GTC 
(guanidine isothiocyanate), 0.01M Tris (pH 7.5), 0.97% (β-Mercaptoethanol)] was then 
added and the tube inverted to mix thoroughly. 350 µl RNA Dilution Buffer was added and 
mixed by inversion. The cleared lysate solution was then transferred to a fresh 
microcentrifuge tube by pipetting ensuring not to disturb the pelleted debris. 200 µl 95% 
ethanol was added to the cleared lysate and mixed by pipetting 3-4 times. The mixture was 
then transferred to the Spin Column Assembly and centrifuged at 14 000 × g for 1 minute at 
r.t. The liquid in the Collection Tube was discarded and the Spin Basket put back into the 
Collection Tube.  
600 µl RNA Wash Solution [60 mM potassium acetate, 10 mM Tris-HCl (pH 7.5 at 
25°C) and 60% ethanol] was added to the Spin Column Assembly and centrifuged at r.t for 1 
minute at 14 000 × g. The Collection Tube was emptied as before and placed on a rack. The 
DNase incubation mix was made by combining 40 µl Yellow Core Buffer [0.0225 M Tris 
(pH 7.5), 1.125 M NaCl and 0.0025% yellow dye], 5 µl 0.09 M MnCl2 and 5 µl of DNase I 
enzyme (in this order) in a sterile tube and mixed gently by pipetting. 50 µl of this DNase 
incubation mix was then applied directly to the membrane inside the Spin Basket ensuring 
that the solution thoroughly covers the membrane. This was then incubated for 15 minutes at 
20-25ºC.  
After the incubation period, 200 µl DNase Stop Solution [2 M GTC, 4mM Tris HCl 
(pH 7.5) and 57% ethanol] was added to the Spin Basket and centrifuged at r.t for 1 minute at 
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14 000 × g. 600 µl RNA Wash Solution was then added and centrifuged at 14 000 × g for 1 
minute at r.t. The Collection Tube was emptied and 250 µl RNA Wash Solution was then 
added and centrifuged at high speed for 2 minutes. The Spin Basket from the Collection tube 
was transferred to a 1.5 ml Elution Tube and 100 µl Nuclease-Free Water added to the 
membrane ensuring that it is completely covered. The Spin Basket Assembly was then placed 
in the centrifuge and centrifuged at 14 000 × g for 1 minute at r.t. The Spin Basket was then 
discarded and the Elution Tube containing purified RNA stored at -70ºC. 
 
3.3.4. Reverse Transcription of Total RNA (First strand DNA synthesis) 
After total RNA was extracted, first strand cDNA was synthesized using the 
GoScript™ Reverse Transcription System (Promega). Each component was mixed and 
briefly centrifuged before use. 4 µl experimental RNA (40 µg/ml) was combined with 1 µl 
Primer Oligo (dT)15 (500 µg/ml, 0.5 µg/reaction). This was then heated to 70ºC in a heating 
block for 5 minutes and immediately chilled on ice for 5 minutes. The mixture was 
centrifuged for 10 seconds in a microcentrifuge and stored on ice until reverse transcription 
mix was added.  
The reverse transcription reaction mix was prepared as per manufacturer’s 
instructions (15µl for each cDNA reaction) and components  briefly combined on ice in the 
following order: 4.0 µl GoScript 5X Buffer, 1.5 µl MgCl2 (25 mM), 1.0 µl PCR Nucleotide 
Mix (10 mM, final concentration 0.5 mM each dNTP), 0.5 µl Recombinant RNasin® 
Ribonuclease Inhibitor (40 U/µl), 1.0 µl GoScript™ Reverse Transcriptase and 7 µl 
Nuclease-Free Water. 15 µl of reverse transcription mix and 5µl of RNA and primer mix 
were combined. Reverse transcription PCR was conducted in a thermal cycler and 
amplification conditions were as follows: annealing at 25ºC for 5 minutes, extension at 42ºC 
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for 1 hour, followed by an incubation extension at 72ºC for 15 minutes to inactivate the 
reverse transcriptase enzyme. 
 
3.3.5. Primer Selection 
The primers were selected according to those used by Couto et al (2008) and 
purchased from Inqaba Biotechnical Industries (Pty) Ltd. Primers chosen had the following 
parameters: length ranged from 18-25 bases, and the Tm (melting temperature) ranged from 
58.35 - 64.52 for the three genes of interest. The primer sets used are described in Table 1. 
 
 
Gene Primer Sequence Size (bp) Reference 
mepA MepA forward ATGTTGCTGCTGCTCTGTTC     718 (Couto, Costa et 
al. 2008) 
 MepA reverse TCAACTGGTCAAACGATCACG   
sepA SepA forward GCAGTCGAGCATTTAATGGA 103 (Couto, Costa et 
al. 2008) 
 SepA reverse ACGTTGTTGCAACTGTGTTAAGA   
gyrA GyrA forward TCGTGCATTGCCAGATGTTCG 394 (Couto, Costa et 
al. 2008) 
 GyrA reverse TCGAGCAGGTAAGACTGACGG   
16S 16S_27 forward AGAGTTTGATCMTGGCTCAG 492 (Lane 1991) 
 16S_519 reverse GWATTACCGCGGCKGCTG   
 
 
Table 3.2. Primers used for the amplification of Staphylococcus aureus efflux pump genes. 
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3.3.6. Optimization of PCR conditions 
Optimization of efflux pump gene amplification was done by changing various 
parameters in the standard PCR protocol. The conditions changed were primer concentration, 
MgCl2 concentration and annealing temperature.  
 
3.3.6.1. Optimization of primer concentration  
Each primer was used at a concentration that ranged from 10-100 pmol/µl. In this 
study, it was found that the optimal primer concentration was 10 pmol/µl for all the primer 
sets used and at this concentration, it was high enough for amplification to take place and low 
enough to prevent any non-specific binding due to the presence of large amounts of unused 
primer.  
 
3.3.6.2. Optimization of MgCl2 concentration 
In order to determine the optimal MgCl2 concentration for each primer set, different 
concentrations of MgCl2 were used and incorporated in the standard PCR reaction procedure. 
The MgCl2 concentrations ranged from 0 to 3mM. The change in MgCl2 volumes was 
rectified by adding the corresponding amount of nuclease-free water to ensure that the final 
volume remained the same. After performing the PCR, the products were run on a 1.5% 
agarose gel for mepA and 2% agarose gel for sepA in order to select the concentration that 
yielded the best results. 
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3.3.6.3. Optimization of annealing temperature 
Optimal annealing temperature was determined using temperatures that ranged from 
53 to 56°C for the three genes. The annealing temperature used for mepA and sepA were 53, 
54, 55 and 56°C, while annealing temperatures of 54 and 56°C were used for gyrA. The 
annealing temperatures were selected by using temperatures that were 5°C lower than the 
melting temperatures (Tm) of the primer sets of the different genes. The subsequent annealing 
temperatures were obtained increasing the temperature in increments of 1°C. Since the lowest 
Tm for both sepA and mepA primer sets was 58.35, an initial annealing temperature of 53ºC 
was used with subsequent 1ºC increments to determine the other annealing temperatures. The 
initial annealing temperature used for gyrA was 54ºC. The optimal annealing temperature for 
16S was not determined as it was the house-keeping gene that was used a positive control and 
produced good results at all temperatures. 
 
3.3.7. PCR conditions used 
The three efflux pump genes including the house-keeping gene (used as a positive 
control) were amplified by PCR with the primers listed in Table 3.2. The reaction mixture, 
which was made up to a final volume of 25 µl, consisted of: 1 µl of cDNA (1.543 µg/ml), 
2.5U (0.5 µl) of Taq Polymerase, 5 µl 5X GoTaq Flexi buffer, 1 µl (10 pmol) of each primer, 
0.5 µl dNTP (10mM) mix and 1.5 mM of MgCl2 (25 mM). The reactions were carried out in 
a thermocycler with the following amplification conditions: DNA was denatured at 95ºC for 
3 minutes, followed by 30 cycles of denaturation at 95ºC for 45 seconds, annealing at 54ºC 
(for sepA) and 56°C (for mepA and gyrA) for 45 seconds, and extension at 72ºC for 45 
seconds, followed by a final extension at 72ºC for 15 minutes. The PCR products were 
diluted, at a ratio of 1:6, with 6 x Blue/Orange loading dye containing [(0.4% (v/v) orange G, 
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0.03% (v/v) bromophenol blue, 0.03% (v/v) xylene cyanol FF, 15% (v/v) Ficoll® 400, 10 
mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0)] and run on a 1% (w/v) agarose gel, 
containing 1 µl Ethidium Bromide, in 1X TBE buffer containing (89 mM tris 
(hydroxymethyl) aminomethane, 0.089 mM boric acid, 2 mM EDTA (pH 8). Electrophoresis 
was done at 80 volts and 2 amps for 50 minutes. The amplification products were visualized 
with a transilluminator under ultraviolet (UV) light and the sizes of the S. aureus genes of 
interest confirmed by comparing their sizes to those of the DNA molecular weight marker.  
 
Reagent Negative control 
(µl) 
16S  (positive control) 
(µl) 
Genes of interest 
(µl) 
cDNA 0 1 1 
dNTP 0.5 0.5 0.5 
MgCl2 1.5 1.5 1.5 
5X flexi buffer 5 5 5 
Forward primer 1 1 1 
Reverse primer 1 1 1 
Go Taq 0.5 0.5 0.5 
Nuclease free Water 15.5 14.5 14.5 
Final volume 25 25 25 
 
 
 
Table 3.3. PCR conditions used in this study. 
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3.4. RESULTS  
3.4.1. Optimization of primer concentration 
At primer concentrations of 50 pmol/µl and 100 pmol/µl, high incidence of primer 
dimers suggested that the primer concentration was too high, resulting in non-specific 
binding. At a primer concentration of 10 pmol/µl, the gel was had less background/smears. 
This showed that the incidence of non-specific binding was reduced, thus resulting in sharper 
bands obtained on the agarose gel (Figures 3.1 to 3.3). Primer dimer incidence was also 
reduced making this the ideal primer concentration for use in this study. 
 
3.4.2. Optimization of MgCl2 concentration 
Magnesium (Mg
2+
) is an essential cofactor for the Taq polymerase enzyme and it 
stabilizes dsDNA (double-stranded DNA). Mg
2+
 concentration is important as it controls 
specificity of the reaction and low Mg
2+
 ion concentrations result in low yields of PCR 
product or cause failure of the reaction, whereas very high concentrations increase chances of 
non-specific products and also promote misincorporation. Since the amount of magnesium 
present in a reaction is very important, magnesium optimization was essential. After MgCl2 
profiling (0 to 3 mM) was done for the three genes, the optimal MgCl2 concentration was 
chosen as being 1.5 mM for sepA (Appendix II, Figure 6) and gyrA for both the MSSA 
ATCC 25923 and MRSA ATCC 33591 strains. MgCl2 profiling for gyrA was required done 
because this gene was easily detected using the initial PCR conditions used. However, the 
optimal MgCl2 concentration for mepA differed for the two strains. The optimal concentration 
for the MSSA ATCC 25923 strain was 1 mM, whereas the MRSA ATCC 33591 strain had an 
optimal MgCl2 concentration of 1.5 mM (Appendix II, figure 5). At these concentrations, the 
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bands produced were sharper and the amount smears due non-specific products was reduced 
compared to the other MgCl2 concentrations.  
 
3.4.3 Optimization of annealing temperature 
 Annealing temperature plays an important role in the gene amplification process as it 
ensures that the primers bind to the gene/product of interest. This helps in the prevention of 
non-specific binding. As described in section 3.2.5.5, the initial annealing temperatures used 
for optimization were 53°C for sepA and mepA and 54°C for gyrA. It was observed that the 
product amplification results obtained for gyrA were the same even at the annealing 
temperatures used for mepA and sepA (Appendix II, Figure 2). Thus annealing temperature 
optimization was mainly done for mepA and sepA. Appendix I, Figures 1 to 4, show the 
results obtained for mepA and sepA at different annealing temperatures. Annealing 
temperatures of 54°C (sepA) and 56°C (mepA and gyrA) were chosen as the amplification 
products obtained had less smears and the bands were sharper on the agarose gel. 
Figures 3.1, 3.2 and 3.3 show PCR amplification results obtained after optimization of 
PCR conditions was done. The conditions used were: primer concentration of 10 pmol/µl, 
MgCl2 concentration of 1mM, for mepA MSSA ATCC 25923, 1.5mM for sepA, gyrA and 
mepA for the MRSA ATCC 33591 strain and annealing temperatures of 54°C (sepA) and 
56°C  (mepA and gyrA).  
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Figure 3.1: 1.5% agarose gel electrophoresis analysis of mepA amplified by 
PCR using gene specific primers. Lane 1 and 5: 100bp DNA molecular 
weight marker; Lanes 2 and 6: no template PCR control (negative control); 
Lanes 3 and 7: mepA gene amplification; Lanes 4 and 8: 16S house-keeping 
gene amplification (internal positive control) for both the MSSA ATCC 
25923 and MRSA ATCC 33591.  
 
Figure 3.2: 1.5% agarose gel electrophoresis analysis of gyrA amplified by PCR 
using gene specific primers. Lane 1 and 5: 100bp DNA molecular weight 
marker; Lanes 2 and 6: no template PCR control (negative control); Lanes 3 and 
7: gyrA gene amplification; Lanes 4 and 8: 16S house-keeping gene amplification 
(internal positive control) for both the MSSA ATCC 25923 and MRSA (ATCC 
33591).  
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3.4.4. Gel electrophoresis and visualization of amplification products 
As described earlier, the percentage of agarose gel is essential in ensuring that the 
PCR products, as well as the DNA molecular marker, separate properly and produce bands 
that are clear and easy to compare. The agarose gel percentages that were eventually chosen 
were 1.5% agarose gel, for mepA and gyrA and 2% for sepA. At these percentages, the bands 
produced were clear and easy to compare and the DNA molecular marker had also separated 
in a way that made it easy to interpret. A 100bp DNA molecular weight marker was run on 
every gel to verify the expected molecular weight of the amplification products. PCR 
products were loaded onto Ethidium Bromide-stained 1.5% and 2% agarose gels amplified at 
annealing temperatures of 54°C and 56°C for both MSSA ATCC 25923 and MRSA ATCC 
33591 strains. The gels were then visualized under UV light in a transilluminator. 
 
Figure 3.3: 2% agarose gel electrophoresis analysis of sepA amplified by 
PCR using gene specific primers. Lane 1 and 5: 100bp DNA molecular 
weight marker; Lanes 2 and 6: no template PCR control (negative control); 
Lanes 3 and 7: sepA gene amplification; Lanes 4 and 8: 16S house-keeping 
gene amplification (internal positive control) for both the MSSA (ATCC 
25923) and MRSA (ATCC 33591). 
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Table 3.4. Presence of mepA, gyrA and sepA in MSSA and MRSA strains on S. aureus  
 MSSA ATCC 25923 MRSA ATCC33591 
mepA + + 
gyrA + + 
sepA - + 
+ detected by PCR 
- not detected by PCR 
 
3.5. DISCUSSION 
In this study, PCR was used to identify and compare the presence of efflux pump 
genes in MSSA ATCC 25923 and MRSA ATCC 33591. Optimization of the PCR was 
essential in ensuring that only products of interest were amplified for easy and effective 
comparison. This was done by changing a various parameters in the reactions such as primer 
concentration, magnesium chloride concentration and annealing temperature. The determined 
optimal primer concentration was 10pmol/μl, as no non-specific amplicons and no primer 
dimers were observed on the agarose gels. After performing a magnesium chloride profile for 
each of the PCR conditions using the optimal 10pmol/μl primer concentration, it was 
observed that the mepA gene in the MSSA ATCC 25923 strain, was detected at a MgCl2 
concentration of 1mM; the other genes were detected at MgCl2 concentrations of 1.5mM for 
both MSSA ATCC 25923 and MRSA ATCC 33591 strains. A 2% agarose gel was used for 
visualization of the sepA gene and a 1.5% agarose gel was used for mepA and gyrA genes. 
The difference in the agarose gel percentage ensured proper separation and visualization of 
PCR amplicons of different sizes. 
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The absence of the sepA gene in the MSSA ATCC 25923 strain under optimal PCR 
conditions, suggests that this efflux pump gene could play a role in conferring resistance 
tothis strain. However, a study carried out by Couto et al. (2008) demonstrated the presence 
of sepA in the ATCC 25923 strain. The discrepancies in results could be attributed to the 
differences in growth conditions and media used as well as the kit employed for total RNA 
extraction (Rneasy Mini Kit QIAGEN) which could have had an effect on the results 
obtained (Couto, Costa et al. 2008). Various studies have been carried out that focus on the 
activity of efflux pumps and their ability to confer resistance to bacteria such as S. aureus. A 
previous study carried out by Narui et al (2002) demonstrated that the sepA gene plays a role 
in the resistance of S. aureus to antiseptics. The study also showed that potential mutations 
that may arise lead to the over-expression of this gene, thereby causing an increase in the 
level of resistance (Narui, Noguchi et al. 2002). Other studies have reported that mepA 
confers resistance to numerous compounds and antibiotics such as biocides, a variety of dyes 
as well as fluoroquinolones (Kaatz, McAleese et al. 2005; McAleese, Petersen et al. 2005). It 
has been shown that mepA expression is regulated by MepR (a transmembrane regulator) 
which is capable of sensing toxic compounds thereby facilitating the expression of mepA 
leading to drug resistance (Kumaraswami, Schuman et al. 2009). 
In addition, numerous earlier studies have shown that NorA is responsible for 
quinolone resistance, which has been shown to arise even in the absence of mutations in 
topoisomerases (Kaatz, Seo et al. 1993; Kaatz and Seo 1995). S. aureus was shown to acquire 
resistance to glycopeptides, such as vancomycin, by attaining the vanA gene from 
Enterococcus faecalis (Weigel, Clewell et al. 2003). The qacA gene, found in S. aureus, has 
been shown to confer multidrug resistance to various dyes such as ethidium bromide, 
antiseptics, disinfectants, benzalkonium chloride and chlohexidine (Littlejohn, Paulsen et al. 
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1992; Leelaporn, Paulsen et al. 1994). Taken together, data clearly show that antibiotic 
resistance in S. aureus is a complex process, involving different genes and mechanisms. 
Multidrug transporters, which are encoded by a number of genes, have also been 
identified in a number of other bacteria such as Bacillus subtilis, where four different 
transporter genes have been identified, namely Bmr, Blt (Neyfakh, Bidnenko et al. 1991; 
Ahmed, Lyass et al. 1995), Bmr3 (Ohki and Murata 1997) and EbrAB (Jack, Storms et al. 
2000; Masaoka, Ueno et al. 2000); the proteins encoded by these genes able to extrude drugs 
from bacterial cells. Streptococcus pneumonia has also been shown to possess 
chromosomally-encoded efflux pump genes mefA or mefE. Here, these MF family EPs play a 
role in macrolide resistance by reducing the internal concentration inside the bacterial cell 
(Sutcliffe, Tait-Kamradt et al. 1996; Tait-Kamradt, Clancy et al. 1997). 
Bacteria are able to acclimatize to different unfavourable environments, such as the 
presence of antibiotics, as a result of their ability to regulate their gene expression processes 
by either horizontal transfer of genetic material or through numerous modifications to their 
genetic sequences (Voss, Loeffen et al. 2005). EP proteins contribute to multidrug resistance 
through their ability to reduce the concentration of the antibiotics by means of antibiotic 
efflux (Li and Nikaido 2009; Villagra, Fuentes et al. 2012). Antibiotic resistance, as a result 
of EP proteins, can be reduced by growing bacteria in cultures containing 
nonphosphotransferase system (PTS) sugars. The latter results in the over-production of other 
genes which, in turn, increases the level of competition with the antibiotic efflux system, 
thereby reducing antibiotic resistance (Villagra, Fuentes et al. 2012).  
The virulence factors employed by a number of bacteria are not fully understood at 
the molecular level (Kumar and Varela 2012). The studies of the different mechanisms, by 
which bacteria are able to cause multidrug resistance, facilitate the development of more 
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effective antibiotics for the treatment of infections (Lewis 1994; Lewis 2001). It is believed 
that the unsupervised and uncontrolled intake of antibiotics is the reason for the development 
of drug resistance, but drug resistance has also been reported in areas where no antibiotics 
have been used (Wright 2007). For example, a recent study carried out by Zhang and 
colleagues (2011) demonstrated the development of antibiotic resistant bacteria during the 
early stage of infant development (Zhang, Kinkelaar et al. 2011). 
Multi-drug efflux pumps found in bacteria play a major role in conferring multi-drug 
resistance (Tennent, Lyon et al. 1989). Studying and understanding the mechanisms by which 
pathogenic bacteria become resistant is important due to the serious health and social 
implications they present (Kumar and Schweizer 2005; Gootz 2010). It is for this reason that 
understanding the ways to inhibit the action of these multi-drug efflux pumps, are vital 
(Lewis 2001; Lomovskaya and Bostian 2006). 
Over-expression of efflux pumps can be induced by the constant presence of 
antibiotics or substrates (Teran, Felipe et al. 2003). Efflux pump proteins also become 
resistant to antibiotics through amino acid substitution in their protein structure. This enables 
them to be more efficient at extruding substances and, just like efflux pump over-expression, 
results in reduced intracellular antibiotic concentrations. As a result, this renders the bacteria 
less susceptible to that compound (Levy 2002; Li and Nikaido 2004; Poole 2005; Piddock 
2006; Stavri, Piddock et al. 2007). A wide variety of compounds and substrates have 
previously been tested in order to assess their ability to hamper the activity of S. aureus EPs. 
This is done in the hope of finding specific inhibitors of these pumps (Kaatz, Seo et al. 1993; 
Neyfakh, Borsch et al. 1993; Kaatz, Moudgal et al. 2003; Kristiansen, Leandro et al. 2003; 
Kristiansen, Leandro et al. 2006). In this study, the presence of three efflux pump genes (the 
mepA, gyrA and sepA) in S. aureus was studied. Results showed that both mepA and gyrA 
were present in both methicillin-sensitive, as well as methicillin-resistant, S. aureus strains. 
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EP gene sepA was only present in the methicillin-resistant S. aureus strain, suggesting that it 
plays a role in conferring resistance to S. aureus.  
Future prospects include performing quantitative Real-Time PCR (RT-PCR) to 
quantify the efflux pump genes as well as investigate the effect of the selected compounds on 
them. 
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Staphylococcus aureus is a Gram-positive coccus first discovered in 1880 in 
Aberdeen, Scotland, by a surgeon by the name of Alexander Ogston (Ogston 1984). It is 
found on the skin, nose and mouth of approximately 20-30% of humans (Jack 2000). It 
causes a wide range of hospital- and community-acquired infections such as deep tissue and 
skin infections (Jack, Storms et al. 2000; Daniyan, Galadima et al. 2011). S. aureus causes 
these diseases because it is able to produce a number of virulence factors, including toxins 
and haemolysing enzymes (Tait-Kamradt, Clancy et al. 1997; Rajaraman, Jack et al. 2000). 
Methicillin-resistant Staphylococcus aureus (MRSA) was reported in 1960, not long after the 
introduction of methicillin (Lewis 2001; Chacon, Estruga et al. 2012). Not only is S. aureus 
resistant to methicillin, but it has also developed resistance to a number of other antibiotics, 
thereby limiting its treatment options (Taylor, Blakely et al. 2008). S. aureus is able to build 
resistance to a wide range of antibiotics through the acquisition of multidrug-resistant (MDR) 
phenotypes, which is associated with increased rates of mortality and morbidity (D'Costa, 
Griffiths et al. 2007; Wright 2007; Wright 2007). 
The ability of bacteria, including S. aureus, to develop resistance to numerous drugs 
has led to some urgency and need to explore other treatment options (Cheng, Gosewehr et al. 
1996; Lomovskaya and Bostian 2006). Plant compounds have been shown to possess 
distinctive antimicrobial activities and are able to enhance the antibacterial activity of various 
drugs (Cushnie and Lamb 2006). Flavonoids are plant products that have a wide distribution 
in plants and are being studied for their wide range of medicinal properties, which include 
possible anti-inflammatory (Serizawa, Osawa et al. 1992), antimicrobial (Tsuchiya, Sato et al. 
1996), and antioxidant (Chung and Ng 2012) properties. Various studies have been conducted 
that outline the antimicrobial activities of flavonoids, including their additive or synergistic 
effects (Barua, Nazeran et al. 2005; Nazeran, Chatlapalli et al. 2005; Stefanovic, Stanojevic et 
al. 2012). 
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S. aureus contains a number of multidrug-resistant efflux pumps that play a role in 
conferring multidrug resistance against numerous antibiotics (Tennent, Lyon et al. 1989; 
Narui, Noguchi et al. 2002). These efflux pumps are encoded by various chromosomal and 
plasmid genes such as mepA, norA, sepA and qacA/B (Kumar and Varela 2012). Efflux 
pumps enable the bacteria to become resistant to antimicrobial agents by reducing their 
intracellular concentration. It has also been established that the slow rate at which efflux 
takes place allows these bacteria to alter the antibiotic target sites (Lewis 2001). It is for this 
reason that developing a suite of new antimicrobial agents to target these efflux mechanisms 
may prove to be beneficial if effective treatments are to be found. (Griffith, Corcoran et al. 
2006).  
The first aim of this study was to determine the minimum inhibitory concentrations 
(MICs) of four antibiotics (tetracycline, ampicillin, methicillin and vancomycin) including 
three flavonoids (chrysin, naringenin and 7-hydroxyflavone), alone and in combination 
against methicillin-sensitive ATCC 25923 (MSSA) and methicillin-resistant ATCC 33591 
(MRSA) S. aureus strains, using Kirby-Bauer disk diffusion and microtitre microdilution 
assays. Synergistic ratios were calculated for the microtitre assay combination results to 
assess wheter any synergistic or additive effects could be identified due to the presence of the 
flavonoids. The second aim was to compare the presence of three efflux pump genes (mepA, 
sepA and gyrA, including the house-keeping gene 16S) in the MSSA ATCC 25923 and 
MRSA ATCC 33591 strains using polymerase chain reaction (PCR). 
For the Kirby-Bauer disk diffusion assay, various concentrations of antibiotics 
tetracycline, ampicillin, methicillin and vancomycin produced inhibitory effects on the 
MSSA ATCC 25923 strain that ranged from susceptible to resistant when compared to the 
MIC interpretive standards for Staphylococcus species as outlined by the Clinical and 
Laboratory Standards Institute (CLSI 2007). The MRSA ATCC 33591 strain was only 
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susceptible to vancomycin. Flavonoids did not show any inhibitory effect on bacterial growth 
in the disk diffusion assay and did not enhance or reduce inhibitory activity of the antibiotics 
in the combination studies. This lack of antibacterial activity exhibited by the flavonoids 
could be attributed to the inability of the flavonoids to effectively diffuse out of the disks 
(Zheng, Tan et al. 1996). However, in the microtitre assay, naringenin did enhance the 
antibacterial activity of tetracycline and ampicillin, as could be observed by the reduction in 
the bacterial growth rates. This was evident as calculated synergistic ratios by the Abbot 
formula showed that naringenin had an additive effect. However, concentrations of 
tetracycline and ampicillin used in the combination studies were those that showed no 
inhibitory effect on bacterial growth.. Chrysin and 7-hydroxyflavone were not used in the 
microdilution assay as they formed precipitates when diluted in the solvent, which would 
have led to unreliable results.  
Since naringenin did show an additive effect when combined with tetracycline and 
ampicillin in the microtitre assay, future work, therefore, is to explore the effect of these 
flavonoid and antibiotic combinations on the expression and overall activity of these efflux 
pumps. This is important as these pumps have previously been implicated in multidrug 
resistance. It has been shown that, in addition to the direct and synergistic antibacterial 
activities of flavonoids, they are also capable of hindering numerous bacterial virulence 
factors such as enzymes, toxins and signal receptors, and can also inhibit the working of 
efflux pumps (Brusco and Nazeran 2005; Cushnie and Lamb 2011). Efflux pump proteins 
coded for by efflux pump genes are responsible for the extrusion of antibiotics thus allowing 
the pathogens to avoid antimicrobial effects (Lomovskaya and Bostian 2006). Recent studies 
have also shown that some flavonoids efficiently inhibit the efflux pumps involved in 
antibiotic resistance in S. aureus (Smith, Kaatz et al. 2007)  
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The presence of efflux pump genes in MSSA ATCC 25923 and MRSA ATCC 33591 
was compared using PCR. However, a lot of optimisation needed to be done in order to 
amplify these specific genes. Primer concentration and magnesium chloride concentration, as 
well as annealing temperature, all had to be optimised for the efflux pump genes to be 
properly amplified and visualised on the agarose gel. Efflux pump genes mepA and gyrA 
were seen in both strains, whereas sepA was only observed in the MRSA ATCC 33591 strain. 
The presence of efflux pump genes in both MSSA ATCC 25923 and MRSA ATCC 33591 
confirms that these genes are present in both sensitive and resistant strains, and that their 
over-expression may lead to the bacteria’s ability to develop drug resistance. It is therefore 
recommended that future studies involve challenging the bacteria with various concentrations 
of antibiotic and naringerin combinations established in this study, to assess the effect that 
this would have on the efflux pump genes. These studies can facilitate the determination of 
which genes are up/down regulated. The function and role of these efflux pump genes can 
also be analyzed by carrying out studies that can knock out the genes in resistant strain and 
determine if the absence would enable the bacteria become susceptible to the various 
antibiotics and flavonoids. 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                  Chapter 4 
146 
 
REFERENCES 
Barua, M., H. Nazeran, et al. (2005). "Classification of Impulse Oscillometric Patterns of 
Lung Function in Asthmatic Children using Artificial Neural Networks." Conf Proc 
IEEE Eng Med Biol Soc 1: 327-331. 
Brusco, M. and H. Nazeran (2005). "Development of an Intelligent PDA-based Wearable 
Digital Phonocardiograph." Conf Proc IEEE Eng Med Biol Soc 4: 3506-3509. 
Chacon, E., A. Estruga, et al. (2012). "Nurses' detection of ineffective inspiratory efforts 
during mechanical ventilation." Am J Crit Care 21(4): e89-93. 
Cheng, P. C., J. A. Gosewehr, et al. (1996). "Potential role of the inactivated X chromosome 
in ovarian epithelial tumor development." J Natl Cancer Inst 88(8): 510-518. 
Chung, P. Y. and G. Y. Ng (2012). "Comparison between an accelerometer and a three-
dimensional motion analysis system for the detection of movement." Physiotherapy 
98(3): 256-259. 
CLSI (2007). "Clinical and Laboratory Standards Institute. Performance Standards for 
Antimicrobial Susceptibility Testing; Seventeenth Information Supplement." CLSI 
M100-S17 [ISBN 1-56238-625-5]: 44-49 and 110-113. 
Cushnie, T. P. and A. J. Lamb (2006). "Assessment of the antibacterial activity of galangin 
against 4-quinolone resistant strains of Staphylococcus aureus." Phytomedicine 13(3): 
187-191. 
Cushnie, T. P. and A. J. Lamb (2011). "Recent advances in understanding the antibacterial 
properties of flavonoids." Int J Antimicrob Agents 38(2): 99-107. 
D'Costa, V. M., E. Griffiths, et al. (2007). "Expanding the soil antibiotic resistome: exploring 
environmental diversity." Curr Opin Microbiol 10(5): 481-489. 
Daniyan, S. Y., M. Galadima, et al. (2011). "In vitro susceptibility profile of Methicillin-
resistant Staphylococcus aureus isolates from clinical specimens to commonly used 
 
 
 
 
                                                                                                                                                                  Chapter 4 
147 
 
antibiotics in Minna, Nigeria." Asian Journal of Pharmaceutical Health Sciences 1(3): 
128-129. 
Griffith, D. C., E. Corcoran, et al. (2006). "Pharmacodynamics of levofloxacin against 
Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: 
do elevated MICs always predict reduced in vivo efficacy?" Antimicrob Agents 
Chemother 50(5): 1628-1632. 
Jack, D. (2000). "Roche calls for potency guidelines to help HIV drug prescribing." Lancet 
356(9241): 1581. 
Jack, D. L., M. L. Storms, et al. (2000). "A broad-specificity multidrug efflux pump requiring 
a pair of homologous SMR-type proteins." J Bacteriol 182(8): 2311-2313. 
Kumar, S. and M. F. Varela (2012). "Biochemistry of bacterial multidrug efflux pumps." Int J 
Mol Sci 13(4): 4484-4495. 
Lewis, K. (2001). "In search of natural substrates and inhibitors of MDR pumps." J Mol 
Microbiol Biotechnol 3(2): 247-254. 
Lomovskaya, O. and K. A. Bostian (2006). "Practical applications and feasibility of efflux 
pump inhibitors in the clinic--a vision for applied use." Biochem Pharmacol 71(7): 
910-918. 
Narui, K., N. Noguchi, et al. (2002). "Cloning and characterization of a novel chromosomal 
drug efflux gene in Staphylococcus aureus." Biol Pharm Bull 25(12): 1533-1536. 
Nazeran, H., S. Chatlapalli, et al. (2005). "Effect of Novel Nanoscale Energy Patches on 
Spectral and Nonlinear Dynamic Features of Heart Rate Variability Signals in 
Healthy Individuals during Rest and Exercise." Conf Proc IEEE Eng Med Biol Soc 5: 
5563-5567. 
Ogston, A. (1984). ""On Abscesses. Classics in Infectious Diseases" " Rev Infect Dis 6(1): 
122-128. 
 
 
 
 
                                                                                                                                                                  Chapter 4 
148 
 
Rajaraman, V., D. Jack, et al. (2000). "A novel quantitative method for 3D measurement of 
Parkinsonian tremor." Clin Neurophysiol 111(2): 338-343. 
Serizawa, S., K. Osawa, et al. (1992). "Relationship between cholesterol sulfate and 
intercellular cohesion of the stratum corneum: demonstration using a push-pull meter 
and an improved high-performance thin-layer chromatographic separation system of 
all major stratum corneum lipids." J Invest Dermatol 99(2): 232-236. 
Smith, E. C., G. W. Kaatz, et al. (2007). "The phenolic diterpene totarol inhibits multidrug 
efflux pump activity in Staphylococcus aureus." Antimicrob Agents Chemother 
51(12): 4480-4483. 
Stefanovic, O. D., D. D. Stanojevic, et al. (2012). "Synergistic antibacterial activity of Salvia 
officinalis and Cichorium intybus extracts and antibiotics." Acta Pol Pharm 69(3): 
457-463. 
Tait-Kamradt, A., J. Clancy, et al. (1997). "mefE is necessary for the erythromycin-resistant 
M phenotype in Streptococcus pneumoniae." Antimicrob Agents Chemother 41(10): 
2251-2255. 
Taylor, P. L., K. M. Blakely, et al. (2008). "Structure and function of sedoheptulose-7-
phosphate isomerase, a critical enzyme for lipopolysaccharide biosynthesis and a 
target for antibiotic adjuvants." J Biol Chem 283(5): 2835-2845. 
Tennent, J. M., B. R. Lyon, et al. (1989). "Physical and biochemical characterization of the 
qacA gene encoding antiseptic and disinfectant resistance in Staphylococcus aureus." 
J Gen Microbiol 135(1): 1-10. 
Tsuchiya, H., M. Sato, et al. (1996). "Comparative study on the antibacterial activity of 
phytochemical flavanones against methicillin-resistant Staphylococcus aureus." J 
Ethnopharmacol 50(1): 27-34. 
 
 
 
 
                                                                                                                                                                  Chapter 4 
149 
 
Wright, G. D. (2007). "The antibiotic resistome: the nexus of chemical and genetic diversity." 
Nat Rev Microbiol 5(3): 175-186. 
Wright, G. D. (2007). "Biochemistry. A new target for antibiotic development." Science 
315(5817): 1373-1374. 
Zheng, W. F., R. X. Tan, et al. (1996). "Two flavones from Artemisia giraldii and their 
antimicrobial activity." Planta Med 62(2): 160-162. 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
                                                                                                                                                                   Appendices 
 
151 
 
APPENDIX I  
 
Kirby-Bauer assay results for flavonoids and antibiotic combinations 
 
 
                                                                       Inhibition zones (mm) 
                                      MSSA ATCC 25923                                 MRSA ATCC 33591 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Ch
r 
 
Na
r 
 
7-
hy 
 
Tet                
+ 
Chr 
 
Tet 
+ 
Nar 
 
Tet 
+ 
7-hy 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Ch
r 
 
Na
r 
 
7-
h
y 
 
Tet                
+ 
Ch
r 
 
Tet
+ 
Na
r 
 
Te
t + 
7-
hy 
0.004 10 10 10 15.3 15.3 15.3 0.004 ─ ─ ─ ─ ─ ─ 
0.008 10 10 10 15.3 15.3 15.3 0.008 ─ ─ ─ ─ ─ ─ 
0.016 10 10 10 15.3 15.3 15.3 0.016 ─ ─ ─ ─ ─ ─ 
0.031 10 10 10 15.3 15.3 15.3 0.031 ─ ─ ─ ─ ─ ─ 
0.063 10 10 10 15.3 15.3 15.3 0.063 ─ ─ ─ ─ ─ ─ 
0.125 10 10 10 15.3 15.3 15.3 0.125 ─ ─ ─ ─ ─ ─ 
0.25 10 10 10 15.3 15.3 15.3 0.25 ─ ─ ─ ─ ─ ─ 
0.5 10 10 10 15.3 15.3 15.3 0.5 ─ ─ ─ ─ ─ ─ 
1 10 10.
5 
10 15.3 15.3 15.3 1 ─ ─ ─ ─ ─ ─ 
2 10 11 10 15.3 15.3 15.3 2 ─ ─ ─ ─ ─ ─ 
 
 
 
 
 
 
 
 
 
 
Table 1. Inhibition zones (mm) of flavonoids (0.004 – 2 mg/ml) in combination with tetracycline 
(1.25 µg/ml) against MSSA ATCC 25923 and MRSA ATCC 33591. 
Chr= chrysin; Nar= naringenin; 7-hy= 7-hydroxyflavone; Tet= tetracycline; ─= no zones of inhibition. 
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                                                                     Inhibition zones (mm) 
                                            MSSA ATCC 25923                                       MRSA ATCC 33591 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Chr 
 
Nar 
 
7-
hy 
 
Am
p                
+ 
Chr 
 
Amp+ 
Nar 
 
Amp 
7-hy 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Ch
r 
 
Na
r 
 
7-
hy 
 
Amp                
+ 
Chr 
 
Am
p + 
Nar 
 
Am
p 
7-hy 
0.004 10 10 10 19 19 19 0.004 ─ ─ ─ 11 11 11 
0.008 10 10 10 19 19 19 0.008 ─ ─ ─ 11 11 11 
0.016 10 10 10 19 19 19 0.016 ─ ─ ─ 11 11 11 
0.031 10 10 10 19 19 19 0.031 ─ ─ ─ 11 11 11 
0.063 10 10 10 19 19 19 0.063 ─ ─ ─ 11 11 11 
0.125 10 10 10 19 19 19 0.125 ─ ─ ─ 11 11 11 
0.25 10 10 10 19 19 19 0.25 ─ ─ ─ 11 11 11 
0.5 10 10 10 19 19 19 0.5 ─ ─ ─ 11 11 11 
1 10 10.5 10 19 19 19 1 ─ ─ ─ 11 11 11 
2 10 11 10 19 19 19 2 ─ ─ ─ 11 11 11 
Table 2. Inhibition zones (mm) of flavonoids (0.004 – 2 mg/ml) in combination with ampicillin (2.5 µg/ml) 
against MSSA ATCC 25923 and MRSA ATCC 33591. 
Chr= chrysin; Nar= naringenin; 7-hy= 7-hydroxyflavone; Amp= ampicillin; ─= no zones of inhibition. 
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                                                                       Inhibition zones (mm) 
                                             MSSA ATCC 25923                                     MRSA ATCC 33591 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Ch
r 
 
Nar 
 
7-
h
y 
 
Me
t                
+ 
Ch
r 
 
Me
t +
Nar 
 
Me
t + 
7-
hy 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Ch
r 
 
Na
r 
 
7-
h
y 
 
Me
t                
+ 
Ch
r 
 
Me
t +
Nar 
 
Me
t + 
7-
hy 
0.004 10 10 10 19 19 19 0.004 ─ ─ ─ ─ ─ ─ 
0.008 10 10 10 19 19 19 0.008 ─ ─ ─ ─ ─ ─ 
0.016 10 10 10 19 19 19 0.016 ─ ─ ─ ─ ─ ─ 
0.031 10 10 10 19 19 19 0.031 ─ ─ ─ ─ ─ ─ 
0.063 10 10 10 19 19 19 0.063 ─ ─ ─ ─ ─ ─ 
0.125 10 10 10 19 19 19 0.125 ─ ─ ─ ─ ─ ─ 
0.25 10 10 10 19 19 19 0.25 ─ ─ ─ ─ ─ ─ 
0.5 10 10 10 19 19 19 0.5 ─ ─ ─ ─ ─ ─ 
1 10 10.
5 
10 19 19 19 1 ─ ─ ─ ─ ─ ─ 
2 10 11 10 19 19 19 2 ─ ─ ─ ─ ─ ─ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Inhibition zones (mm) of flavonoids (0.004 – 2 mg/ml) in combination with methicillin (5 µg/ml) 
against MSSA ATCC 25923 and MRSA ATCC 33591. 
Chr= chrysin; Nar= naringenin; 7-hy= 7-hydroxyflavone; Met= methicillin; ─= no zones of inhibition. 
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                                                                       Inhibition zones (mm) 
                                     MSSA ATCC 25923                                     MRSA ATCC 33591 
 
Flavonoid 
Concentrati
on (mg/ml) 
 
Ch
r 
 
Na
r 
 
7-
hy 
 
Va
n                
+ 
Ch
r 
 
Van
+
Nar 
 
Va
n + 
7-
hy 
 
Flavonoid 
Concentratio
n (mg/ml) 
 
Ch
r 
 
Na
r 
 
7-
h
y 
 
Va
n                
+ 
Ch
r 
 
Va
n + 
Nar 
 
Van
+ 
7-hy 
0.004 10 10 10 14 14 14 0.004 ─ ─ ─ 14 14 14 
0.008 10 10 10 14 14 14 0.008 ─ ─ ─ 14 14 14 
0.016 10 10 10 14 14 14 0.016 ─ ─ ─ 14 14 14 
0.031 10 10 10 14 14 14 0.031 ─ ─ ─ 14 14 14 
0.063 10 10 10 14 14 14 0.063 ─ ─ ─ 14 14 14 
0.125 10 10 10 14 14 14 0.125 ─ ─ ─ 14 14 14 
0.25 10 10 10 14 14 14 0.25 ─ ─ ─ 14 14 14 
0.5 10 10 10 14 14 14 0.5 ─ ─ ─ 14 14 14 
1 10 10.
5 
10 14 14 14 1 ─ ─ ─ 14 14 14 
2 10 11 10 14 14 14 2 ─ ─ ─ 14 14 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Inhibition zones (mm) of flavonoids (0.004 – 2 mg/ml) in combination with vancomycin (5 
µg/ml) against MSSA ATCC 25923 and MRSA ATCC 33591. 
Chr= chrysin; Nar= naringenin; 7-hy= 7-hydroxyflavone; Van= vancomycin; ─= no zones of inhibition. 
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APPENDIX II 
 
PCR Optimization results 
 
 
Annealing temperature of 53°C 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 1% agarose gel analysis of mepA and sepA amplified using gene specific 
primers at annealing temperature of 53°C and primer concentration of 10 pmol/µl. 
Lanes 1 and 10: 100bp DNA molecular weight marker; Lanes 2-4- mepA gene 
amplification- no template PCR control (negative control), for MSSA ATCC 25923 
and MRSSA (ATCC 33591) strains respectively; Lanes 5-7: sepA gene amplification- 
no template PCR conrol (negative control), MSSA ATCC 25923 and MRSA ATCC 
33591 strains respectively; Lanes 8 and 9: 16S, house-keeping gene amplification 
(internal positive control) for both MSSA ATCC 25923 and MRSA ATCC 33591 
strains respectively.  
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Annealing temperature of 54°C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. 1% agarose gel analysis of mepA and sepA amplified using gene specific 
primers at annealing temperature of 54°C and primer concentration of 10 pmol/µl. 
Lanes 1 and 13: 100bp DNA molecular weight marker; Lanes 2-4: mepA gene 
amplification- no template PCR control (negative control), MSSA ATCC 25923 
and MRSSA (ATCC 33591) strains respectively; Lanes 5-7: sepA gene 
amplification- no template PCR conrol (negative control), for MSSA ATCC 25923 
and MRSA ATCC 33591 strains respectively; Lanes 8: 10- gyrA gene 
amplification- no template PCR control (negative control), MSSA ATCC 25923 
and MRSA ATCC 33591 strains respectively; Lanes 11 and 12: 16S, house-keeping 
gene amplification (internal positive control) for both MSSA ATCC 25923 and 
MRSA ATCC 33591 strains respectively.  
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Annealing temperature of 55°C 
 
 
 
 
 
 
 
 
 
 
Annealing temperature of 56°C 
 
 
 
 
 
 
 
 
 
Figure 1. 1% agarose gel analysis of mepA and sepA amplified using gene specific 
primers at annealing temperature of 55°C and primer concentration of 10 pmol/µl. 
Lanes 1 and 10: 100bp DNA molecular weight marker; Lanes 2-4: mepA gene 
amplification- no template PCR control (negative control), for MSSA ATCC 25923 
and MRSSA (ATCC 33591) strains respectively; Lanes 5-7: sepA gene 
amplification- no template PCR conrol (negative control), for MSSA ATCC 25923 
and MRSA ATCC 33591 strains respectively; Lanes 8 and 9: 16S, house-keeping 
gene amplification (internal positive control) for both MSSA ATCC 25923 and 
MRSA ATCC 33591 strains respectively.  
 
Figure 1. 1% agarose gel analysis of mepA and sepA amplified using gene 
specific primers at annealing temperature of 56°C and primer 
concentration of 10 pmol/µl. Lane 1: 100bp DNA molecular weight 
marker; Lanes 2-4: mepA gene amplification- no template PCR control 
(negative control), for MSSA ATCC 25923 and MRSSA (ATCC 33591) 
strains respectively; Lanes 5-7: sepA gene amplification- no template PCR 
conrol (negative control), for MSSA ATCC 25923 and MRSA ATCC 
33591 strains respectively; Lanes 8 and 9: 16S, house-keeping gene 
amplification (internal positive control) for both MSSA ATCC 25923 and 
MRSA ATCC 33591 strains respectively.  
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Magnesium Chloride concentration mepA 
 
 
 
 
 
 
 
 
Magnesium Chloride concentration sepA 
 
 
 
 
Figure 5. 1.5% agarose gel elecrophoresis of mepA magnesium chloride 
concentration optimization amplified using gene specific primers. Lanes 1 and 
10: 100bp DNA molecular weight marker; Lane 2- no template PCR control 
(negative control); Lanes 3-9: magnesium chloride at concentrations of 0, 0.5, 1, 
1.5, 2, 2.5 and 3mM respectively. (A) MSSA ATCC 25923 and (B)  MRSA 
ATCC 33591 strains.  
 
Figure 6. 2% agarose gel elecrophoresis of sepA magnesium chloride 
concentration optimization amplified using gene specific primers. Lane 1: 
100bp DNA molecular weight marker; Lanes 2-8: magnesium chloride at 
concentrations of 0, 0.5, 1, 1.5, 2, 2.5 and 3mM respectively. (A) MSSA 
ATCC 25923 and (B) MRSA ATCC 33591.  
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Appendix III 
Summary of antibiotic resistance  
Resistance to β-lactams and methicillin 
 
 
 
 
 
 
 
 
 
(a) Induction of staphylococcal β-lactamase synthesis in the presence of the β-lactam antibiotic 
penicillin. I. The DNA-binding protein BlaI binds to the operator region, thus repressing RNA 
transcription from both blaZ and blaR1- blaI. In the absence of penicillin, β-lactamase is expressed at 
low levels. II. Binding of penicillin to the transmembrane sensor-transducer BlaR1 stimulates BlaR1 
autocatalytic activation. III–IV. Active BlaR1 either directly or indirectly (via a second protein, 
BlaR2) cleaves BlaI into inactive fragments, allowing transcription of both blaZ and blaR1-blaI to 
commence. V–VII. β-Lactamase, the extracellular enzyme encoded by blaZ (V), hydrolyzes the β-
lactam ring of penicillin (VI), thereby rendering it inactive (VII). (b) Mechanism of S. aureus 
resistance to methicillin. Synthesis of PBP2a proceeds in a fashion similar to that described for β-
lactamase. Exposure of MecR1 to a β-lactam antibiotic induces MecR1 synthesis. MecR1 inactivates 
MecI, allowing synthesis of PBP2a. MecI and BlaI have coregulatory effects on the expression of 
PBP2a and β-lactamase.  
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Resistance to vancomycin 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanisms of S. aureus resistance to vancomycin: VISA strains. VISA strains appear to be 
selected from isolates that are heterogeneously resistant to vancomycin. These VISA strains 
synthesize additional quantities of peptidoglycan with an increased number of D-Ala-DAla 
residues that bind vancomycin, preventing the molecule from getting to its bacterial target. 
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Resistance to vancomycin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mechanisms of S. aureus resistance to vancomycin: VRSA strains. VRSA strains are resistant to 
Vancomycin because of the acquisition of the vanA operon from an enterococcus that allows synthesis 
of a cell wall precursor that ends in D-Ala-D-Lac dipeptide rather than D-Ala-D-Ala. The new 
dipeptide has dramatically reduced affinity for vancomycin. In the presence of vancomycin, the novel 
cell wall precursor is synthesized, allowing continued peptidoglycan assembly. 
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Appendix IV 
Summary of the structures of flavonoids  
 
         
 
The skeleton structures of the main classes of flavonoids: aurones , isoflavones  (e.g. Sophoraisoflavone 
A), chalcones (e.g. Licochalcone A), flavanones  (e.g. Naringenin), flavones (e.g. Chrysin), flavonols (e.g. 
Galangin), flavanon-3-ols (e.g. Dihydrofisetin), anthocyanidins , flavan-3-ols (e.g. Epigallocatechin), 
proanthocyanidins (occur as dimers, trimers, tetramers and pentamers; R=0, 1, 2 or 3 flavan-3-ol 
structures), flavans (e.g. 6,4'-Dichloroflavan) flavan-3,4-diols (e.g. Leucocyanidin) and dihydrochalcones. 
 
 
 
 
 
 
 
 
